{ "style": "corporate", "slides": [ { "body": { "children": [ { "span": 3, "content": { "url": "https://r2.bankops.ai/generated/1772025012029-4b8aba6670d2.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#012179" }, { "span": 9, "children": [ { "span": 4 }, { "span": 4, "content": { "bold": false, "font": "Garamond", "runs": [ { "text": "Discussion Materials\n" }, { "text": "March 2026", "fontSize": 1600 } ], "text": "Discussion Materials\nMarch 2026", "type": "text", "anchor": "ctr", "fontSize": 2200, "_maxChars": 265, "_maxLines": 5, "_overflow": false, "_charCount": 31, "_lineCount": 2, "_charsPerLine": 53 } }, { "span": 4, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "Hypothetical Investment Bank" } ], "text": "Hypothetical Investment Bank", "type": "text", "align": "r", "color": "#012179", "anchor": "b", "fontSize": 2200, "_maxChars": 265, "_maxLines": 5, "_overflow": false, "_charCount": 28, "_lineCount": 1, "_charsPerLine": 53 } } ], "direction": "col" } ], "direction": "row" }, "type": "grid" }, { "body": { "gap": 0, "children": [ { "gap": 0.05, "span": 8, "padding": 0.15, "children": [ { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "1.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "State of Play: Biotech's Qualified Recovery", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 43, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "2.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "The Barbell Thesis: Why the Middle Will Be Left Behind", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 54, "_lineCount": 2, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "3.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Force #1: The $300B Patent Cliff Imperative", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 43, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "4.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Force #2: GLP-1 Wars & the Incretin Revolution", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 46, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "5.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Force #3: China's Rise as an Innovation Superpower", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 50, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "6.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Force #4: FDA Turbulence and Regulatory Recalibration", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 53, "_lineCount": 2, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "7.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Where Capital Is Actually Flowing: Platform vs. Asset Companies", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 63, "_lineCount": 2, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "8.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "The M&A Landscape: Buyers, Targets & Deal Dynamics", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 50, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "9.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Themes Worth Watching: Beyond GLP-1", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 35, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" }, { "gap": 0.05, "children": [ { "span": 2, "content": { "font": "Garamond Bold", "text": "10.", "type": "text", "align": "ctr", "color": "#012179", "anchor": "ctr", "fontSize": 2200, "_maxChars": 5, "_maxLines": 1, "_overflow": false, "_charCount": 3, "_lineCount": 1, "_charsPerLine": 5 } }, { "span": 10, "content": { "font": "Garamond Bold", "text": "Investment Implications & Actionable Takeaways", "type": "text", "color": "#405363", "anchor": "ctr", "fontSize": 1400, "_maxChars": 104, "_maxLines": 2, "_overflow": false, "_charCount": 46, "_lineCount": 1, "_charsPerLine": 52 } } ], "direction": "row" } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772024946596-414192eaa27c.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#012179" } ], "direction": "row" }, "type": "grid", "title": "Agenda", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_titleCharCount": 6, "_titleLineCount": 1, "_titleCharsPerLine": 41 }, { "type": "grid", "footer": "Selected representative transactions. Past results not indicative of future performance.", "$template": "dashboard", "sectionLabel": "FIRM CREDENTIALS", "$templateData": { "kpis": [ { "label": "Transactions Closed", "value": "200+" }, { "label": "Aggregate Deal Value", "value": "$85B+" }, { "label": "Senior Bankers", "value": "40+" }, { "label": "Biotech Sector Focus", "value": "25 yrs" } ], "title": "HC & Life Sciences Investment Banking", "leftPanel": { "header": "Biopharma M&A Deal Volume & Avg Premium (2019\u20132025E)", "content": { "bars": [ { "data": [ 95, 80, 120, 65, 95, 145, 160 ], "name": "Deal Volume ($B)" } ], "type": "chart", "lines": [ { "data": [ 52, 55, 68, 52, 61, 72, 78 ], "name": "Avg. Acq. Premium (%)" } ], "dualAxis": true, "chartType": "combo", "categories": [ "2019", "2020", "2021", "2022", "2023", "2024", "2025E" ] } }, "rightPanel": { "header": "Selected Completed Transactions", "content": { "data": { "rows": [ [ "Pfizer", "Seagen", "$43.0B", "2023" ], [ "AbbVie", "ImmunoGen", "$10.1B", "2024" ], [ "Bristol-Myers", "RayzeBio", "$4.1B", "2024" ], [ "AbbVie", "Cerevel Tx", "$8.7B", "2024" ], [ "AstraZeneca", "Gracell Bio", "$1.2B", "2024" ], [ "Eli Lilly", "Aktis Oncology", "$1.4B", "2024" ], [ "Novartis", "MorphoSys", "$2.9B", "2024" ], [ "Summit Tx", "Akeso AK112", "$5.0B", "2023" ] ], "headers": [ "Acquirer", "Target", "Value", "Year" ], "colAlign": [ "l", "l", "r", "ctr" ] }, "type": "table" } } } }, { "body": { "children": [ { "span": 6, "children": [ { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Seagen", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 6, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028652276-69f5c6c1cafd.jpg", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Seagen logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Acquired by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028652867-01edb28dcf28.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Pfizer logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2023", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "ImmunoGen", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 9, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028653598-fa3b963eb594.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "ImmunoGen logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Acquired by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028654186-b2b3be064adb.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "AbbVie logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "RayzeBio", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 8, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028654757-162e1d5c1c57.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "RayzeBio logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Acquired by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028655335-a8c64dc576a3.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Bristol-Myers Squibb logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" } ], "direction": "col" }, { "span": 6, "children": [ { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Cerevel Tx", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 10, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028655896-f4c23cc8e17c.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Cerevel Tx logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Acquired by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028656721-08273db0912a.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "AbbVie logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Gracell Bio", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028657340-d00a60e6f235.jpg", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Gracell Bio logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Acquired by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028657923-6288be3775e3.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "AstraZeneca logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Aktis Oncology", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 14, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028658642-b9a0823098da.jpg", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Aktis Oncology logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Acquired by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028659224-3f6ee42a2f08.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Eli Lilly logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" } ], "direction": "col" }, { "span": 6, "children": [ { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "MorphoSys", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 9, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028663032-059dc78aa752.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "MorphoSys logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Fairness opinion\nfor acquisition by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": true, "_charCount": 35, "_lineCount": 2, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028665715-490d3b9a6375.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Novartis logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Akeso AK112", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028668847-64c1f8bbe1cb.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Akeso AK112 logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Licensed to", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028671568-0e7069e3b4ea.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Summit Therapeutics logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2023", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Iovance Bio", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 11, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028676242-ff48b4ea6133.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Iovance Bio logo" } }, { "span": 1, "content": { "font": "Arial", "text": "IPO & follow-on\nmanaged by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": true, "_charCount": 26, "_lineCount": 2, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028687514-06d3508b1794.jpg", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Lead Manager logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2024", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" } ], "direction": "col" }, { "span": 6, "children": [ { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Relay Tx", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 8, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028689361-89ade16cddc4.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Relay Tx logo" } }, { "span": 1, "content": { "font": "Arial", "text": "PIPE financing\nmanaged by", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": true, "_charCount": 25, "_lineCount": 2, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028689978-06d3508b1794.jpg", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Lead Manager logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2023", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Protagonist Tx", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 14, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028697410-3de979a09d50.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Protagonist Tx logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Strategic advisory\nfor", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": true, "_charCount": 22, "_lineCount": 2, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028701399-c886d01aebcb.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Undisclosed Buyer logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2025", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" }, { "gap": 0.02, "span": 4, "border": "#999999", "padding": 0.05, "children": [ { "span": 2, "content": { "font": "Arial Bold", "text": "Merus N.V.", "type": "text", "align": "ctr", "color": "#405363", "anchor": "b", "fontSize": 600, "_maxChars": 45, "_maxLines": 1, "_overflow": false, "_charCount": 10, "_lineCount": 1, "_charsPerLine": 45 } }, { "span": 1, "content": { "type": "line", "color": "#999999", "width": 6350 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028706103-16ec0d834001.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Merus N.V. logo" } }, { "span": 1, "content": { "font": "Arial", "text": "Strategic advisory\nfor", "type": "text", "align": "ctr", "color": "#405363", "anchor": "ctr", "fontSize": 600, "_maxChars": 47, "_maxLines": 1, "_overflow": true, "_charCount": 22, "_lineCount": 2, "_charsPerLine": 47 } }, { "span": 3, "content": { "url": "https://r2.bankops.ai/search/1772028706906-c886d01aebcb.png", "type": "image", "source": "search", "objectFit": "contain", "searchTerm": "Undisclosed Buyer logo" } }, { "span": 2, "content": { "font": "Arial", "text": "2025", "type": "text", "align": "ctr", "color": "#666666", "anchor": "t", "fontSize": 800, "_maxChars": 35, "_maxLines": 1, "_overflow": false, "_charCount": 4, "_lineCount": 1, "_charsPerLine": 35 } } ], "direction": "col" } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Selected Biotech Transactions", "footer": "Selected representative transactions. Includes roles as lead advisor, co-advisor and fairness opinion provider. Past results not indicative of future performance.", "sectionLabel": "FIRM CREDENTIALS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 29, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "children": [ { "span": 6, "border": "#012179", "margin": 0.4, "content": { "text": "\u201cThe team brought genuine depth to our process. They knew every relevant strategic buyer in oncology and helped us navigate a competitive auction with precision. The outcome exceeded our expectations on price and fit.\u201d\n\nChief Executive Officer\nMid-cap oncology company \u2014 sell-side M&A", "type": "text", "align": "ctr", "anchor": "ctr", "fontSize": 1100, "_maxChars": 624, "_maxLines": 12, "_overflow": false, "_charCount": 284, "_lineCount": 8, "_charsPerLine": 52 } } ], "direction": "row" }, { "span": 6, "children": [ { "span": 6, "border": "#012179", "margin": 0.4, "content": { "text": "\u201cWe interviewed six banks. This was the only team that could speak credibly to GLP-1 acquirers and frame our platform story in a way that resonated. That expertise was decisive in closing the right deal at the right valuation.\u201d\n\nFounder & CEO\nMetabolic disease biotech \u2014 sell-side M&A", "type": "text", "align": "ctr", "anchor": "ctr", "fontSize": 1100, "_maxChars": 624, "_maxLines": 12, "_overflow": false, "_charCount": 284, "_lineCount": 8, "_charsPerLine": 52 } } ], "direction": "row" } ], "direction": "row" }, { "span": 5, "content": { "url": "https://r2.bankops.ai/generated/1772028713025-453721fe8cbd.png", "type": "image", "prompt": "Clean professional dark navy blue abstract background with subtle scientific molecular structure pattern, suitable for investment banking presentation", "source": "ai" } } ], "direction": "col" }, "type": "grid", "title": "What Our Clients Are Saying", "sectionLabel": "FIRM CREDENTIALS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_titleCharCount": 27, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "type": "grid", "$template": "sectionTitle", "$templateData": { "name": "STATE OF PLAY", "number": "1.", "panelColor": "#4472C4" } }, { "body": { "children": [ { "span": 4, "children": [ { "span": 5, "header": "Sector Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Late-2025 M&A Deal Value", "value": "$36B+", "sublabel": "Signals renewed confidence" }, { "label": "Patent Cliff (2025\u20132030)", "value": "$300B", "sublabel": "Forces Big Pharma to buy" }, { "label": "GLP-1 Alliances in 2024", "value": "$30B+", "sublabel": "Single category dominance" }, { "label": "Biotech Index Off 2021 Peak", "value": "~70%", "sublabel": "But recovery underway" } ] }, "_headerMaxChars": 28 }, { "span": 7, "header": "Key Narrative", "content": { "type": "bulletList", "items": [ "Green shoots are real but recovery is narrow \u2014 platforms and validated mechanisms win", "Big Pharma holds $500B+ acquisition firepower; the patent cliff makes M&A existential", "IPO window cautiously reopening after near-total closure in 2022\u201323", "Venture capital bifurcating sharply: AI-enabled platforms win; preclinical single-assets lose", "XBI remains ~30% below its 2021 peak \u2014 sentiment improving but reset is not fully reversed" ], "fontSize": 1000, "_maxChars": 640, "_maxLines": 16, "_overflow": false, "_charCount": 420, "_lineCount": 14, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 120 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 8, "header": "XBI (Biotech Index) Recovery \u2014 Multi-Year Context", "content": { "type": "chart", "series": [ { "data": [ 100, 82, 62, 48, 55, 58, 68, 63, 74, 78, 85 ], "name": "XBI (Indexed, Jan 2021 = 100)" } ], "smooth": true, "chartType": "line", "lineColor": "#4472C4", "lineWidth": 3, "categories": [ "Jan '21", "Jul '21", "Jan '22", "Jul '22", "Jan '23", "Jul '23", "Jan '24", "Jul '24", "Jan '25", "Jul '25", "Jan '26" ], "gridBottom": 25, "showLineValues": false }, "_headerMaxChars": 59 } ], "direction": "row" }, "type": "grid", "title": "Biotech 2026: Recovery Real, Not Broad", "footer": "Source: Evaluate Pharma 2026 Preview; EY Firepower Report; FactSet", "sectionLabel": "STATE OF PLAY", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 6, "padding": 0.1, "children": [ { "span": 7, "header": "Winners: Where Capital Is Flowing", "content": { "type": "bulletList", "items": [ "Platform biotech with broad applicability (mRNA, ADC, cell therapy platforms)", "Validated mechanisms with Phase 2+ human proof-of-concept data", "Obesity/metabolic \u2014 GLP-1, GIP, amylin, and combination approaches", "Oncology with differentiated mechanism or biomarker selectivity", "China-originated IP in bispecifics, ADCs, and GLP-1 analogs finding Western buyers" ], "fontSize": 1000, "_maxChars": 915, "_maxLines": 15, "_overflow": false, "_charCount": 350, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 61, "_maxCharsPerItem": 183 }, "_headerMaxChars": 42 }, { "span": 5, "header": "Winner Signals", "content": { "type": "statGrid", "items": [ { "label": "Avg. M&A Premium (platform)", "value": "3.2x", "sublabel": "vs. 0.7x for single-asset Ph1" }, { "label": "GLP-1 Alliance Value (2024)", "value": "$30B+", "sublabel": "One category, one year" }, { "label": "ADC Deals Signed (2023\u201325)", "value": "40+", "sublabel": "Fastest-growing modality" }, { "label": "Platform Biotech Valuation Premium", "value": "58%", "sublabel": "Over asset-centric peers" } ] }, "_headerMaxChars": 42 } ], "direction": "col", "background": "#EBF3FF" }, { "span": 6, "padding": 0.1, "children": [ { "span": 7, "header": "Losers: Where Capital Is Scarce", "content": { "type": "bulletList", "items": [ "Single-asset biotechs without clear acquirer rationale or line-of-sight to Phase 3", "CNS programs that lack compelling biomarkers or patient selection strategy", "Companies reliant on 2021-era valuation frameworks to raise follow-on rounds", "Mid-cap biotechs with one approved product but no pipeline \u2014 one-hit wonders", "Broad-indication oncology programs without genomic or biomarker hook" ], "fontSize": 1000, "_maxChars": 915, "_maxLines": 15, "_overflow": false, "_charCount": 376, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 61, "_maxCharsPerItem": 183 }, "_headerMaxChars": 42 }, { "span": 5, "header": "Loser Signals", "content": { "type": "statGrid", "items": [ { "label": "Single-asset IPOs (2024)", "value": "~60%", "sublabel": "Trading below issue price" }, { "label": "Mid-cap biotech avg. cash runway", "value": "14mo", "sublabel": "Down from 24mo in 2021" }, { "label": "VC follow-on rate (pre-Ph2)", "value": "31%", "sublabel": "Lowest since 2015" }, { "label": "Mushy middle down-rounds (2024)", "value": "2.1x", "sublabel": "Rise vs. prior year" } ] }, "_headerMaxChars": 42 } ], "direction": "col", "background": "#FFF3F3" } ], "direction": "row" }, "type": "grid", "title": "The Market Recovery Is Bifurcated", "footer": "Source: Evaluate Pharma, J.P. Morgan Healthcare Conference 2026 observations", "sectionLabel": "STATE OF PLAY", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 33, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Biotech IPO Volume & Proceeds 2018\u20132025 ($B)", "content": { "type": "chart", "series": [ { "data": [ 5.1, 6.4, 15.3, 24.1, 2.2, 1.8, 4.6, 7.2 ], "name": "IPO Proceeds ($B)" }, { "data": [ 49, 58, 87, 133, 18, 14, 32, 48 ], "name": "# of IPOs" } ], "stacked": false, "chartType": "bar", "categories": [ "2018", "2019", "2020", "2021", "2022", "2023", "2024", "2025E" ], "gridBottom": 60, "showBarValues": false }, "_headerMaxChars": 52 }, { "span": 6, "header": "Follow-On & Crossover Financing Dynamics", "content": { "data": { "rows": [ [ "Biotech IPOs (#)", "133", "18", "14", "32", "\u2191 cautious reopen" ], [ "Avg. IPO raise ($M)", "$312", "$198", "$156", "$228", "\u2191 selectivity up" ], [ "Crossover rounds (#)", "210", "62", "44", "78", "\u2191 gating signal" ], [ "Down-rounds (% of all)", "8%", "34%", "41%", "29%", "\u2193 still elevated" ], [ "Median cash runway (mo.)", "28", "20", "16", "14", "\u2193 still squeezed" ] ], "headers": [ "Metric", "2021 Peak", "2022", "2023", "2024", "Trend" ], "fontSize": 900, "colWidths": [ 5, 2, 2, 2, 2, 4 ], "rowHeight": 0.27, "_cellMaxChars": [ 25, 8, 8, 8, 8, 19 ], "_headersMaxChars": [ 50, 16, 16, 16, 16, 38 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 5, "header": "Who Gets Funded in 2025", "content": { "data": { "rows": [ [ "AI platform biotech", "$80M+", "$200M+" ], [ "ADC / payload platform", "$65M", "$150M" ], [ "GLP-1 / metabolic", "$55M", "$130M" ], [ "Single-asset oncology Ph2", "$35M", "$80M" ], [ "Single-asset preclinical", "$18M", "Rare/down" ], [ "CNS (no biomarker)", "$15M", "Rare" ] ], "headers": [ "Company Type", "Avg. Series A", "Avg. Series B" ], "fontSize": 900, "colWidths": [ 6, 3, 3 ], "rowHeight": 0.21, "_cellMaxChars": [ 31, 13, 13 ], "_headersMaxChars": [ 62, 26, 26 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 6 }, "_headerMaxChars": 36 }, { "span": 7, "header": "What This Means for the Market", "content": { "type": "bulletList", "items": [ "The IPO window has reopened, but only for a narrow band of companies \u2014 platform stories and clinical-stage assets with de-risked data", "Crossover rounds are the new gating mechanism: no crossover = no IPO; crossover investors are picking winners 12-18 months early", "Down-round frequency at 29% in 2024 is nearly 4x the 2021 level \u2014 a large cohort of 2020-21 vintage companies is being written down or wound up", "Cash runway compression is forcing forced M&A and licensing on acquirer terms \u2014 the best time to be a buyer in 15 years" ], "fontSize": 1000, "_maxChars": 832, "_maxLines": 16, "_overflow": false, "_charCount": 523, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 208 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "The Financing Reset: Capital Is Unequal", "footer": "Source: BioPharma Catalyst, Evaluate Pharma, SVB Healthcare Financing Report 2025, FactSet.", "sectionLabel": "STATE OF PLAY", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 39, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 7, "header": "Biotech Bear-Recovery Cycles: Peak-Indexed", "content": { "type": "chart", "series": [ { "data": [ 100, 68, 42, 35, 38, 44, 52, 61, 70, 78, 88 ], "name": "2000 Genomics Bubble" }, { "data": [ 100, 72, 58, 62, 74, 85, 94, 102, 110, 115, 120 ], "name": "2008 Financial Crisis" }, { "data": [ 100, 74, 65, 70, 82, 91, 98, 104, 109, 114, 118 ], "name": "2015\u201316 Valuation Reset" }, { "data": [ 100, 62, 48, 52, 58, 65, 74, 80, null, null, null ], "name": "2021\u202226 ZIRP Unwind (Current)" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "0", "6m", "12m", "18m", "24m", "30m", "36m", "42m", "48m", "54m", "60m" ], "gridBottom": 30, "showLineValues": false }, "_headerMaxChars": 52 }, { "span": 5, "header": "Cycle Comparison: Key Statistics", "content": { "data": { "rows": [ [ "2000 Bubble", "-78%", "2002", "6\u20137 yrs", "Genomics/personalized medicine" ], [ "2008 Crisis", "-52%", "2009", "3\u20134 yrs", "Biologics era; biosimilar law" ], [ "2015\u201316 Reset", "-55%", "2016", "2\u20133 yrs", "Immuno-oncology wave (PD-1)" ], [ "2021\u201326 (Now)", "-70%", "2022", "3\u20135 yrs?", "GLP-1 + AI + patent cliff M&A" ] ], "headers": [ "Cycle", "Peak-to-Trough", "Trough", "Recovery to Peak", "Catalyst" ], "fontSize": 900, "colWidths": [ 3, 3, 2, 3, 6 ], "rowHeight": 0.27, "_cellMaxChars": [ 13, 13, 8, 13, 30 ], "_headersMaxChars": [ 26, 26, 16, 26, 60 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 4 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "What Each Recovery Had in Common", "content": { "type": "cardGrid", "items": [ { "lines": [ "Every durable recovery had a new scientific paradigm: genomics, biologics, immuno-oncology. Today: GLP-1 + AI" ], "title": "A Defining Catalyst" }, { "lines": [ "Big Pharma M&A accelerated each prior recovery by recycling capital into the ecosystem and validating valuations" ], "title": "M&A as the Ignition" }, { "lines": [ "In every cycle, <20% of companies that crashed fully recovered. The rest were acquired, merged, or wound down" ], "title": "Survivors Were Narrow" }, { "lines": [ "The 2016 reset looked like prolonged malaise until PD-1 data broke; the 2021 reset may resolve the same way" ], "title": "Timing Is Hard" } ] }, "_headerMaxChars": 36 }, { "span": 6, "header": "Our Read on the Current Cycle", "content": { "type": "bulletList", "items": [ "At month 42 of the current cycle, we're tracking closest to the 2015\u201316 reset \u2014 not the catastrophic 2000 bubble", "The defining catalysts are already in place: GLP-1 is the immuno-oncology of this decade; AI drug discovery is the genomics bet", "Unlike prior cycles, M&A has front-loaded the recovery for a narrow set of winners \u2014 the rest may wait significantly longer", "Contrarian view: the median biotech is not recovering \u2014 only the top quartile is. Investors pricing in a broad recovery are wrong" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 491, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Where Are We in the Cycle: Comps", "footer": "Source: FactSet, BioCentury, Evaluate Pharma. XBI indexed to 100 at each cycle peak.", "sectionLabel": "STATE OF PLAY", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 32, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "type": "grid", "$template": "sectionTitle", "$templateData": { "name": "THE BARBELL THESIS", "number": "2.", "panelColor": "#2F5496" } }, { "body": { "children": [ { "span": 3, "children": [ { "span": 6, "header": "Left Bell: Mega-Cap Acquirers", "content": { "type": "bulletList", "items": [ "Eli Lilly, AbbVie, J&J, AZ, Pfizer: $500B+ firepower", "Patent cliff = urgency to pay 50\u2013100% premiums", "Prefer Phase 2/3 with clear indication synergies" ], "fontSize": 1000, "_maxChars": 183, "_maxLines": 3, "_overflow": false, "_charCount": 146, "_lineCount": 3, "lineSpacing": 0.9, "_charsPerLine": 61, "_maxCharsPerItem": 61 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 42 }, { "span": 6, "header": "Right Bell: Innovative Platforms", "content": { "type": "bulletList", "items": [ "mRNA, ADC, cell therapy platforms attract premiums", "AI drug discovery: Recursion, Relay, Insilico", "China innovators: bispecifics, ADCs, GLP-1 analogs" ], "fontSize": 1000, "_maxChars": 183, "_maxLines": 3, "_overflow": false, "_charCount": 145, "_lineCount": 3, "lineSpacing": 0.9, "_charsPerLine": 61, "_maxCharsPerItem": 61 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 42 } ], "direction": "row" }, { "span": 9, "header": "The Barbell Dynamic: Conceptual Framework", "content": { "type": "aiHtml", "htmlData": "

MEGA-CAP PHARMA

Eli Lilly \u00b7 AbbVie \u00b7 AZ \u00b7 J&J \u00b7 Pfizer

$500B+

Acquisition capacity

THE SQUEEZED MIDDLE

Mid-cap single-asset biotechs
trapped without clear exit path

PLATFORM INNOVATORS

mRNA \u00b7 ADC \u00b7 Cell Therapy \u00b7 AI Drug Discovery

10\u201320x

Platform premiums

Strategy: Hunt & Acquire

Buy validated late-stage assets at premium; patent cliff creates urgency

Strategy: Capital Desert

Can't raise equity at sustainable prices; too small for Big Pharma interest

Strategy: Build & Partner

Attract licensing deals and equity from growth-hungry partners

" }, "_headerMaxChars": 92 } ], "direction": "col" }, "type": "grid", "title": "The Barbell: Extremes Win, Middle Loses", "footer": "Source: EY Firepower Report 2026; FactSet; Evaluate Pharma", "sectionLabel": "THE BARBELL THESIS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 39, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 5, "children": [ { "span": 6, "header": "The Cost of Capital Trap", "content": { "type": "bulletList", "items": [ "Post-2022 rate environment raised biotech WACC to 12\u201315% \u2014 Phase 2 NPVs collapse", "Mid-caps must dilute heavily to raise cash; each round resets valuation anchor lower", "Public market comps no longer support 2021 multiples; down-rounds normalized" ], "fontSize": 1000, "_maxChars": 468, "_maxLines": 9, "_overflow": false, "_charCount": 240, "_lineCount": 6, "lineSpacing": 1.3, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 }, { "span": 6, "header": "The Acquirer Threshold Problem", "content": { "type": "bulletList", "items": [ "Big Pharma M&A desks screen for $5B+ peak sales potential \u2014 most mid-caps can't clear the bar", "Single-asset Phase 2 companies lack the risk distribution that makes a large deal pencil out", "Preferred targets: de-risked Phase 3 or approved assets with clean IP and global rights" ], "fontSize": 1000, "_maxChars": 468, "_maxLines": 9, "_overflow": false, "_charCount": 272, "_lineCount": 6, "lineSpacing": 1.3, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" }, { "span": 7, "children": [ { "span": 6, "header": "Structural Forces Converging on the Middle", "content": { "type": "chart", "series": [ { "data": [ 22, 26, 28, 20, 16, 14, 13 ], "name": "Mid-cap biotech avg. cash runway (months)" } ], "barColor": "#E94040", "chartType": "bar", "categories": [ "2019", "2020", "2021", "2022", "2023", "2024", "2025E" ], "gridBottom": 25, "horizontal": false, "showBarValues": true, "valueDecimals": 0 }, "_headerMaxChars": 52 }, { "span": 6, "header": "The Death Valley Dynamics", "content": { "type": "bulletList", "items": [ "VC pulls back from preclinical: Series A average now requires Phase 1 data", "Crossover funds demand near-term catalyst visibility before participating in IPOs", "IRA drug pricing reform hits single-product mid-caps hardest \u2014 peak sales assumptions cut 20\u201335%", "Result: companies in the middle face a capital desert with no clear path to exit or independence" ], "fontSize": 1000, "_maxChars": 693, "_maxLines": 9, "_overflow": false, "_charCount": 347, "_lineCount": 7, "lineSpacing": 1.3, "_charsPerLine": 77, "_maxCharsPerItem": 154 }, "_headerMaxChars": 52 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Why the Middle Gets Squeezed", "footer": "Source: SVB Leerink, Evaluate Pharma, FactSet 2025", "sectionLabel": "THE BARBELL THESIS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 28, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "header": "Left Bell: Mega-Cap Acquirers", "content": { "data": { "rows": [ [ "Eli Lilly", "$70B+", "GLP-1, obesity, immunology", "Morphic ($3.2B), Versanis" ], [ "AbbVie", "$60B+", "Immunology, oncology, neuroscience", "ImmunoGen ($10.1B), Cerevel ($8.7B)" ], [ "AstraZeneca", "$50B+", "Oncology, ADCs, rare disease", "Fusion Pharma, Gracell Bio" ], [ "Johnson & Johnson", "$55B+", "Oncology, immunology, MedTech", "Ambrx ($2B), NM26 bispecific" ], [ "Pfizer", "$50B+", "Oncology, RSV, mRNA pipeline", "Seagen ($43B), Arena Pharma" ] ], "headers": [ "Company", "Firepower ($B)", "Key Target Modalities", "Recent Move" ], "fontSize": 900, "colWidths": [ 4, 3, 5, 5 ], "rowHeight": 0.28, "_cellMaxChars": [ 36, 26, 46, 46 ], "_headersMaxChars": [ 72, 52, 92, 92 ] }, "type": "table", "_maxRows": 8, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 92 }, { "span": 5, "header": "Right Bell: Platform Innovators", "content": { "data": { "rows": [ [ "Moderna", "mRNA", "Platform breadth beyond COVID; oncology pipeline" ], [ "Daiichi Sankyo", "ADC", "Best-in-class linker tech; AZ partnership validates" ], [ "Recursion", "AI drug discovery", "Platform economics; Roche/Bayer partnerships" ], [ "BioNTech", "mRNA / oncology", "Individualized neoantigen cancer vaccines Ph3" ] ], "headers": [ "Company", "Platform", "Why It Wins" ], "fontSize": 900, "colWidths": [ 4, 4, 9 ], "rowHeight": 0.22, "_cellMaxChars": [ 36, 36, 85 ], "_headersMaxChars": [ 72, 72, 170 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 4 }, "_headerMaxChars": 92 } ], "direction": "col" }, "type": "grid", "title": "The Barbell in Practice: Named Companies", "footer": "Source: Public filings, FactSet, Evaluate Pharma 2025. For illustrative purposes.", "sectionLabel": "THE BARBELL THESIS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 40, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "3." } ], "text": "3.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "THE $300B PATENT CLIFF", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 22, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772024967315-b15d1ffac756.png", "type": "image", "prompt": "professional subtle luxury small molecule pattern with color #012179", "source": "ai" }, "background": "#4472C4" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Revenue at Risk by Year", "content": { "type": "chart", "series": [ { "data": [ 28, 45, 62, 58, 55, 52 ], "name": "Revenue Losing Exclusivity ($B)" } ], "barColor": "#C0392B", "chartType": "bar", "categories": [ "2025", "2026", "2027", "2028", "2029", "2030" ], "gridBottom": 25, "valuePrefix": "$", "valueSuffix": "B", "showBarValues": true }, "_headerMaxChars": 52 }, { "span": 6, "header": "Key Drugs Losing Exclusivity (2025\u20132028)", "content": { "data": { "rows": [ [ "Keytruda", "Merck", "Oncology (PD-1)", "$25B+" ], [ "Humira (post-LoE)", "AbbVie", "Immunology", "$14B" ], [ "Eliquis", "BMS/Pfizer", "Anticoagulant", "$12B" ], [ "Stelara", "J&J", "Immunology", "$11B" ], [ "Enbrel", "Pfizer/Amgen", "Immunology", "$7B" ] ], "headers": [ "Drug", "Company", "Indication", "Peak Sales" ], "fontSize": 900, "colWidths": [ 3, 3, 3, 3 ], "rowHeight": 0.3, "_cellMaxChars": [ 20, 20, 20, 20 ], "_headersMaxChars": [ 40, 40, 40, 40 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Strategic Response Archetypes", "content": { "type": "cardGrid", "items": [ { "lines": [ "Pfizer/Seagen ($43B), AbbVie/Cerevel ($8.7B)", "Acquire blockbuster potential at scale" ], "title": "Transformational M&A" }, { "lines": [ "Phase 2/3 assets in core therapeutic area", "Lower risk, faster pipeline integration" ], "title": "Bolt-On Acquisition" }, { "lines": [ "AbbVie's Skyrizi/Rinvoq post-Humira", "New formulations, indications, combos" ], "title": "Lifecycle Extension" }, { "lines": [ "Fast, cheaper pipeline access", "BMS, Pfizer, AZ all in market for deals" ], "title": "China Licensing" } ] }, "_headerMaxChars": 36 }, { "span": 6, "header": "My View: Urgency = Premium Pricing", "content": { "type": "bulletList", "items": [ "Merck alone faces $25B+ Keytruda expiry by 2028 \u2014 willingness to pay 80%+ premium", "AbbVie's Humira transition is the blueprint: Skyrizi/Rinvoq replace $14B", "Companies that missed 2023 dip face even steeper acquisition competition" ], "fontSize": 1000, "_maxChars": 588, "_maxLines": 12, "_overflow": false, "_charCount": 225, "_lineCount": 6, "lineSpacing": 0.9, "_charsPerLine": 49, "_maxCharsPerItem": 196 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 34 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "The $300B Patent Cliff Imperative", "footer": "Source: Evaluate Pharma Portfolio Tactics Report, Oct 2025; Evaluate 2026 Preview", "sectionLabel": "THE $300B PATENT CLIFF", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 33, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$260B", "sublabel": "As of Jan 2026" }, { "label": "2024 Revenue", "value": "$63.6B", "sublabel": "+7% YoY" }, { "label": "Keytruda Revenue", "value": "$29.5B", "sublabel": "46% of total sales" }, { "label": "Patent Expiry", "value": "2028", "sublabel": "US exclusivity cliff" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "The Core Problem", "content": { "type": "bulletList", "items": [ "Keytruda is the world\u2019s best-selling drug \u2014 and Merck\u2019s single largest dependency", "US patent expires 2028; biosimilar entry could erode 60\u201380% of revenue within 3 years", "No single pipeline asset comes close to replacing $29B in annual revenue", "Merck must acquire or partner its way out \u2014 urgency creates premium willingness" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 317, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 117 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Keytruda Revenue Trajectory & Cliff", "content": { "type": "chart", "series": [ { "data": [ 14.4, 17.2, 20.9, 25, 29.5, 32, 33.5, 32, 24, 14, 8 ], "name": "Keytruda Revenue ($B)" } ], "smooth": true, "chartType": "line", "lineColor": "#C0392B", "lineWidth": 3, "categories": [ "2020", "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E", "2028E", "2029E", "2030E" ], "gridBottom": 25, "showLineValues": false }, "_headerMaxChars": 35 }, { "span": 6, "header": "Pipeline: What Can Fill the Gap?", "content": { "data": { "rows": [ [ "MK-1084", "Oncology combo", "Phase 2", "~$3-5B" ], [ "Clesrovimab", "Infant RSV", "Filed", "~$1-2B" ], [ "Sotatercept", "PAH", "Approved", "~$3B" ], [ "MK-7684A", "NSCLC", "Phase 3", "~$4-6B" ], [ "Efineptazone", "CNS/Alzheimer", "Phase 2", "Speculative" ] ], "headers": [ "Asset", "Indication", "Stage", "Peak Sales Est." ], "fontSize": 900, "colWidths": [ 4, 4, 3, 4 ], "rowHeight": 0.27, "_cellMaxChars": [ 14, 14, 10, 14 ], "_headersMaxChars": [ 28, 28, 20, 28 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "M&A Firepower", "content": { "type": "statGrid", "items": [ { "label": "Cash & Equivalents", "value": "$13B", "sublabel": "End of Q3 2024" }, { "label": "Estimated Debt Capacity", "value": "$35B", "sublabel": "At current leverage" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Recent Deals", "content": { "type": "bulletList", "items": [ "Prometheus Bio ($10.8B) \u2014 autoimmune, TL1A", "Acceleron ($11.5B) \u2014 sotatercept, PAH", "Harpoon Therapeutics ($680M) \u2014 T-cell engager", "Eyebiotech \u2014 retinal disease, early bolt-on" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 167, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Merck & Co.: Racing the Keytruda Clock", "footer": "Source: Merck 10-K 2024, Evaluate Pharma, FactSet. Market data as of Jan 2026.", "sectionLabel": "THE $300B PATENT CLIFF", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 5, "header": "The Revenue Gap Merck Must Fill ($B)", "content": { "type": "chart", "series": [ { "data": [ 63.6, 67, 58, 42, 62 ], "name": "Total Revenue" } ], "barColor": "#4472C4", "chartType": "bar", "categories": [ "2024A", "2026E", "2028E (cliff)", "2030E w/o M&A", "2030E w/ M&A" ], "gridBottom": 40, "horizontal": false, "valuePrefix": "$", "valueSuffix": "B", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 52 }, { "span": 7, "header": "What Merck Must Acquire to Stay Whole", "content": { "data": { "rows": [ [ "$5B+ peak sales potential", "Only assets this size offset Keytruda erosion" ], [ "Oncology or immunology fit", "Leverages commercial infra and KOL relationships" ], [ "Phase 2/3 or approved", "2028 cliff: 3-4yr window; early-stage too slow" ], [ "Clean global rights", "Merck competes globally; ex-US rights critical" ], [ "No direct Keytruda overlap", "Avoid over-concentration in PD-1 pathway" ] ], "headers": [ "Criteria", "Why It Matters for Merck" ], "fontSize": 900, "colWidths": [ 5, 8 ], "rowHeight": 0.27, "_cellMaxChars": [ 33, 55 ], "_headersMaxChars": [ 66, 110 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 5, "header": "Illustrative Acquisition Candidates", "content": { "data": { "rows": [ [ "Seagen (done)", "ADC platform; acquired $43B", "Acquired" ], [ "Incyte", "JAK/oncology; Jakafi LOE", "~$14B" ], [ "Protagonist Tx", "Rusfertide, hematology", "~$3B" ], [ "Karuna (BMS)", "CNS; diversification", "Acquired" ], [ "Argenx", "FcRn platform; immunology", "~$28B" ] ], "headers": [ "Company", "Rationale", "Mkt Cap" ], "fontSize": 900, "colWidths": [ 4, 6, 3 ], "rowHeight": 0.25, "_cellMaxChars": [ 17, 28, 12 ], "_headersMaxChars": [ 34, 56, 24 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 36 }, { "span": 7, "header": "Our View", "content": { "type": "bulletList", "items": [ "Merck is the most acute case of patent cliff urgency in pharma \u2014 no company has more riding on a single asset", "The pipeline partially offsets the gap but cannot close it alone; at least one $10\u201320B deal is likely by 2026", "Willingness to pay 70\u201390% premiums is rational given the alternative: permanent revenue step-down", "Ideal targets: late-stage oncology or immunology with global rights and $5B+ commercial potential" ], "fontSize": 1000, "_maxChars": 832, "_maxLines": 16, "_overflow": false, "_charCount": 412, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 208 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Merck: M&A Strategy & Target Framework", "footer": "Source: Evaluate Pharma, SVB Leerink, company filings. Views are analytical, not recommendations.", "sectionLabel": "THE $300B PATENT CLIFF", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$320B", "sublabel": "As of Jan 2026" }, { "label": "2024 Revenue", "value": "$56.3B", "sublabel": "+3% YoY post-Humira" }, { "label": "Humira Peak (2022)", "value": "$21.2B", "sublabel": "Since biosimilar entry" }, { "label": "Skyrizi + Rinvoq", "value": "$18B+", "sublabel": "2024 combined revenue" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "Why AbbVie Is the Blueprint", "content": { "type": "bulletList", "items": [ "Humira biosimilar entry in 2023 was the most-anticipated patent cliff in pharma history", "AbbVie spent 2018\u20132022 quietly building Skyrizi (risankizumab) and Rinvoq (upadacitinib) into blockbusters", "Result: revenue barely dipped; Skyrizi/Rinvoq now growing faster than Humira ever did", "The market underestimated execution quality \u2014 AbbVie stock hit all-time highs post-cliff" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 366, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 117 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Humira Decline vs. Successor Ramp", "content": { "type": "chart", "series": [ { "data": [ 19.2, 19.8, 20.7, 21.2, 14, 8.9, 6, 4.5, 3.5 ], "name": "Humira" }, { "data": [ 1.4, 1.8, 3.3, 5.8, 8.7, 11.1, 13.5, 15.5, 17 ], "name": "Skyrizi" }, { "data": [ 0.9, 1.2, 1.9, 2.8, 3.6, 5, 6.5, 8, 9.5 ], "name": "Rinvoq" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2019", "2020", "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E" ], "gridBottom": 60, "showLineValues": false }, "_headerMaxChars": 35 }, { "span": 6, "header": "The Transition Mechanics", "content": { "data": { "rows": [ [ "Anticipation", "2016-2019", "Pharmacyclics acq; seeded IL-23" ], [ "Build", "2019-2022", "Skyrizi/Rinvoq: 8+ approvals each" ], [ "Transition", "2023", "Absorbed $7B drop; partial offset" ], [ "Recovery", "2024-now", "Skyrizi to beat Humira peak 2027" ] ], "headers": [ "Phase", "Years", "What AbbVie Did" ], "fontSize": 900, "colWidths": [ 3, 3, 7 ], "rowHeight": 0.27, "_cellMaxChars": [ 12, 12, 33 ], "_headersMaxChars": [ 24, 24, 66 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 4 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "AbbVie Firepower", "content": { "type": "statGrid", "items": [ { "label": "Cash & Equivalents", "value": "$12B", "sublabel": "End of Q3 2024" }, { "label": "Free Cash Flow (2024)", "value": "$18B+", "sublabel": "Funds future M&A" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Recent Acquisitions", "content": { "type": "bulletList", "items": [ "ImmunoGen ($10.1B) \u2014 ELAHERE ADC, ovarian cancer", "Cerevel ($8.7B) \u2014 CNS; emraclidine schizophrenia", "Landos Biopharma \u2014 GI inflammation", "Syndesi Therapeutics \u2014 CNS synaptic modulation" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 176, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "AbbVie: The Patent Cliff Playbook", "footer": "Source: AbbVie 10-K 2024, Evaluate Pharma, FactSet. Market data as of Jan 2026.", "sectionLabel": "THE $300B PATENT CLIFF", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 33, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "AbbVie Revenue Bridge: Humira to Next Cycle ($B)", "content": { "type": "chart", "series": [ { "data": [ 21.2, 14, 8.9, 6, 3, 1.5 ], "name": "Humira" }, { "data": [ 8.6, 12.3, 16.1, 20, 26.5, 30 ], "name": "Skyrizi + Rinvoq" }, { "data": [ 15, 16, 17, 18.5, 21, 24 ], "name": "Other (oncology/neuro)" } ], "stacked": true, "chartType": "bar", "categories": [ "2022 Peak", "2023", "2024", "2025E", "2027E", "2029E" ], "gridBottom": 60, "horizontal": false, "showBarValues": false }, "_headerMaxChars": 52 }, { "span": 6, "header": "What AbbVie Must Do Next", "content": { "data": { "rows": [ [ "Skyrizi/Rinvoq LOE (2030s)", "~10 years runway", "Seed next cycle via early M&A" ], [ "Cerevel CNS execution", "Emraclidine Phase 3", "Schizophrenia $8B+; binary risk" ], [ "ImmunoGen ADC integration", "ELAHERE growing", "Platform vs. one-product TBD" ], [ "Neuroscience buildout", "Post-Allergan: Botox", "Migraine/psych = diversification" ], [ "China generic exposure", "Adalimumab biosimilars", "Mostly priced in" ] ], "headers": [ "Challenge", "Status", "Implication" ], "fontSize": 900, "colWidths": [ 4, 4, 5 ], "rowHeight": 0.27, "_cellMaxChars": [ 26, 26, 33 ], "_headersMaxChars": [ 52, 52, 66 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Lessons for the Sector", "content": { "type": "cardGrid", "items": [ { "lines": [ "AbbVie began successor development 7+ years before Humira LoE", "Most companies wait too long" ], "title": "Start Early" }, { "lines": [ "Skyrizi (IL-23) and Rinvoq (JAK1) are mechanistically superior to Humira in some indications" ], "title": "Bet on Mechanism, Not Brand" }, { "lines": [ "Pharmacyclics ($21B) wasn\u2019t a replacement \u2014 it was diversification that bought time" ], "title": "M&A as Acceleration" }, { "lines": [ "Market chronically underestimates how good large pharma commercial teams are at product launches" ], "title": "Execution Is Alpha" } ] }, "_headerMaxChars": 36 }, { "span": 6, "header": "Our View", "content": { "type": "bulletList", "items": [ "AbbVie proves patent cliffs are survivable with right lead time and pipeline discipline", "Market still prices most pharma cliffs as terminal; AbbVie shows that's wrong", "Key risk: Cerevel's emraclidine Phase 3 failure would reset CNS thesis and remove diversification", "AbbVie template: expect Merck, BMS, Pfizer to follow same playbook with 2-4 year lags" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 346, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "AbbVie: Next Chapter & Market Lessons", "footer": "Source: AbbVie investor day 2024, Evaluate Pharma, SVB Leerink. Views are analytical.", "sectionLabel": "THE $300B PATENT CLIFF", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 37, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "4." } ], "text": "4.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "GLP-1 WARS", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 10, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772024988623-10ffeee1bfaf.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#4472C4" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 5, "children": [ { "span": 5, "header": "The Numbers Tell the Story", "content": { "type": "statGrid", "items": [ { "label": "Lilly's Projected '26 Rx Sales", "value": "$75.5B", "sublabel": "Pharma's first-ever milestone" }, { "label": "GLP-1 Alliances in 2024", "value": "$30B+", "sublabel": "Single-year record" }, { "label": "GLP-1 Programs in Pipeline", "value": "500+", "sublabel": "Global, all stages" }, { "label": "China's Pipeline Share", "value": ">40%", "sublabel": "GLP-1 programs globally" } ] }, "_headerMaxChars": 36 }, { "span": 7, "header": "GLP-1 Entering a Combination Era", "content": { "type": "bulletList", "items": [ "The next frontier isn't better GLP-1s \u2014 it's GLP-1 + muscle preservation (myostatin inhibitors, ACVR2B)", "Amylin analogs (Cagrilintide) are the real sleeper \u2014 preserve muscle while losing fat", "NASH/MASH is GLP-1's next battleground after obesity; $35B+ opportunity by 2030", "Oral GLP-1 formulation will disrupt injectable market \u2014 Pfizer, Lilly, BioHaven racing", "Investors overvaluing pure GLP-1 plays; combo-mechanism companies are underappreciated" ], "fontSize": 1000, "_maxChars": 735, "_maxLines": 15, "_overflow": false, "_charCount": 439, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 49, "_maxCharsPerItem": 147 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 34 } ], "direction": "col" }, { "span": 7, "children": [ { "span": 5, "header": "GLP-1 Market Leaders vs. Challengers", "content": { "data": { "rows": [ [ "Eli Lilly", "Tirzepatide", "Approved", "GLP-1/GIP; SURPASS data" ], [ "Novo Nordisk", "Semaglutide", "Approved", "SELECT CV; first-mover" ], [ "Novo Nordisk", "CagriSema", "Phase 3", "GLP-1+amylin combo" ], [ "AstraZeneca", "AZD5004", "Phase 2", "Oral mol. GLP-1" ], [ "Pfizer", "Danuglipron", "Phase 2", "Once-daily oral GLP-1" ] ], "headers": [ "Company", "Asset", "Stage", "Differentiation" ], "fontSize": 900, "colWidths": [ 3, 3, 2, 4 ], "rowHeight": 0.25, "_cellMaxChars": [ 20, 20, 12, 28 ], "_headersMaxChars": [ 40, 40, 24, 56 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 }, { "span": 7, "header": "GLP-1 vs. Broader Metabolic Pipeline Deal Value", "content": { "type": "chart", "series": [ { "data": [ 2.1, 5.4, 8.8, 18.2, 30.4 ], "name": "GLP-1 Alliances ($B)" }, { "data": [ 4.5, 7.2, 11, 22, 38 ], "name": "Broader Metabolic ($B)" } ], "stacked": false, "chartType": "bar", "categories": [ "2020", "2021", "2022", "2023", "2024" ], "gridBottom": 45, "showBarValues": false }, "_headerMaxChars": 52 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "GLP-1 Is Reshaping the Entire Drug Market", "footer": "Source: Evaluate Pharma GLP-1 Dealmaking Report Nov 2025; Evaluate 2026 Preview; Company filings", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 41, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 7, "header": "Full Competitive Landscape by Mechanism", "content": { "data": { "rows": [ [ "Eli Lilly", "Tirzepatide", "GLP-1/GIP", "Appr.", "Best-in-class" ], [ "Eli Lilly", "Retatrutide", "GLP-1/GIP/Gcg", "Ph3", "Triple; 24% loss" ], [ "Novo Nordisk", "Semaglutide", "GLP-1", "Appr.", "SELECT CV" ], [ "Novo Nordisk", "CagriSema", "GLP-1+amylin", "Ph3", "Muscle-preserving" ], [ "AstraZeneca", "AZD5004", "GLP-1 (oral)", "Ph2", "Oral QD" ], [ "Pfizer", "Danuglipron", "GLP-1 (oral)", "Ph2", "Oral QD dosing" ], [ "Amgen", "MariTide", "GLP-1/GIP antag", "Ph3", "Monthly dosing" ], [ "Structure Tx", "GSBR-1290", "GLP-1/GIP bspec", "Ph2", "Long-act bispfc" ], [ "Boehringer", "Survodutide", "GLP-1/Gcg", "Ph3", "NASH focus" ], [ "Roche/Carmot", "CT-388", "GLP-1/GIP", "Ph2", "Acq $2.7B; depth" ] ], "headers": [ "Company", "Asset", "Mechanism", "Stage", "Key Edge" ], "fontSize": 900, "colWidths": [ 4, 4, 4, 2, 4 ], "rowHeight": 0.24, "_cellMaxChars": [ 18, 18, 18, 7, 18 ], "_headersMaxChars": [ 36, 36, 36, 14, 36 ] }, "type": "table", "_maxRows": 19, "_overflow": false, "_rowCount": 10 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 4, "header": "Why Lilly Is Pulling Away", "content": { "type": "bulletList", "items": [ "Tirzepatide's dual mechanism: ~20% weight loss vs. ~15% for semaglutide", "Retatrutide Phase 3: ~24% weight loss \u2014 new ceiling", "Manufacturing scale-up outpaced Novo; supply constraints ease by 2025", "Cardio outcomes data due 2026 \u2014 final gap vs. Novo's SELECT advantage" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 260, "_lineCount": 7, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 }, "_headerMaxChars": 36 }, { "span": 4, "header": "Novo's Defensive Moat", "content": { "type": "bulletList", "items": [ "SELECT CV outcomes trial (2023) - only completed MACE data for GLP-1s", "Payer coverage cemented by outcomes evidence", "CagriSema targets muscle-preservation gap vs pure GLP-1s", "Oral semaglutide gaining traction; pipeline positions Novo for next wave" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 241, "_lineCount": 7, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 }, "_headerMaxChars": 36 }, { "span": 4, "header": "Total GLP-1 Market 2030E", "content": { "type": "statGrid", "items": [ { "label": "GLP-1 Market 2030E", "value": "$130B+", "sublabel": "Up from $34B in 2024" }, { "label": "# of Approved GLP-1s by 2028", "value": "10+", "sublabel": "Obesity + cardiometabolic" } ] }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "The GLP-1 Wars: Competitive Battlemap", "footer": "Source: Evaluate Pharma, GlobalData, company filings, ClinicalTrials.gov Jan 2026.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 37, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 5, "children": [ { "span": 6, "header": "GLP-1 Generation Map", "content": { "data": { "rows": [ [ "Gen 1", "GLP-1 mono", "Semaglutide", "~15%" ], [ "Gen 2", "GLP-1 / GIP", "Tirzepatide", "~20%" ], [ "Gen 3", "GLP-1/GIP/Gcg", "Retatrutide", "~24%" ], [ "Gen 3+", "GLP-1 + amylin", "CagriSema", "~25%*" ], [ "Gen 4", "GLP-1 + muscle", "Various", "TBD" ], [ "Oral", "Small-mol GLP-1", "Danuglipron", "~10%" ] ], "headers": [ "Generation", "Mechanism", "Best-in-Class", "Weight Loss" ], "fontSize": 900, "colWidths": [ 3, 4, 4, 3 ], "rowHeight": 0.27, "_cellMaxChars": [ 11, 16, 16, 11 ], "_headersMaxChars": [ 22, 32, 32, 22 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 6 }, "_headerMaxChars": 36 }, { "span": 6, "header": "Adjacent Opportunities GLP-1 Unlocks", "content": { "type": "bulletList", "items": [ "NASH/MASH: GLP-1 + FXR agonist combinations; Madrigal (Rezdiffra) leads but GLP-1s threatening", "Heart failure: FLOW trial showed semaglutide reduces HF hospitalization \u2014 new indication filing", "Sleep apnea: Lilly/Novo both filing; ~20M undiagnosed US patients, no drug therapy exists", "Addiction/CNS: GLP-1 receptors in reward circuits; Novo exploring alcohol/opioid use disorder", "CKD: FLOW renal outcomes trial could unlock nephrology market worth $15B+" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 444, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 104 }, "_headerMaxChars": 36 } ], "direction": "col" }, { "span": 7, "children": [ { "span": 6, "header": "Investment Angles: Who Benefits Beyond Lilly & Novo", "content": { "data": { "rows": [ [ "Viking Therapeutics", "VK2735 oral+inject", "Best pure-play challenger" ], [ "Structure Tx", "GSBR-1290 oral", "Chinese-origin oral GLP-1" ], [ "Altimmune", "Pemvidutide", "GLP-1/Gcg; NASH+obesity" ], [ "Carmot (Roche)", "CT-388/CT-868", "Roche platform; acq. valid." ], [ "Zealand Pharma", "Petrelintide", "Pure amylin; Novo partner" ], [ "Inventiva", "Lanifibranor", "NASH adjacent PPAR agonist" ] ], "headers": [ "Company", "GLP-1 Angle", "Our Take" ], "fontSize": 900, "colWidths": [ 4, 5, 5 ], "rowHeight": 0.21, "_cellMaxChars": [ 24, 31, 31 ], "_headersMaxChars": [ 48, 62, 62 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 6 }, "_headerMaxChars": 52 }, { "span": 6, "header": "Our Contrarian View on GLP-1", "content": { "type": "bulletList", "items": [ "Consensus is too focused on the Lilly/Novo duopoly \u2014 the real alpha is in the next-gen mechanism companies and oral challengers", "Oral GLP-1 will be the single largest catalyst for market expansion: 500M+ addressable patients globally who won't self-inject", "GLP-1 for CNS and addiction is the most underappreciated adjacency \u2014 3-5 year horizon but massive if it works", "Muscle preservation (GLP-1 + myostatin/amylin) is the key differentiator in the next generation; pure GLP-1 plays commoditize" ], "fontSize": 1000, "_maxChars": 1001, "_maxLines": 13, "_overflow": false, "_charCount": 487, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 77, "_maxCharsPerItem": 231 }, "_headerMaxChars": 52 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Next-Gen GLP-1: Beyond Semaglutide", "footer": "Source: Evaluate Pharma, NEJM clinical data, SVB Leerink GLP-1 deep-dive 2025.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 34, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$750B", "sublabel": "Largest pharma globally" }, { "label": "2024 Revenue", "value": "$45.0B", "sublabel": "+32% YoY" }, { "label": "Mounjaro Revenue", "value": "$11.5B", "sublabel": "Type 2 diabetes" }, { "label": "Zepbound Revenue", "value": "$5.0B", "sublabel": "Obesity; approved Nov 2023" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "The Lilly Thesis", "content": { "type": "bulletList", "items": [ "Tirzepatide (GLP-1/GIP) best-in-class weight loss drug \u2014 20%+ body weight reduction", "Retatrutide Phase 3 showed 24% weight loss \u2014 no competitor close", "Lilly closed manufacturing gap vs. Novo; supply no longer constraint", "Pipeline diversification: oncology (Jaypirca), immunology, Alzheimer's (donanemab)", "Revenue trajectory toward $75B+ in 2026 \u2014 unprecedented for pharma" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 363, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 78 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Incretin Revenue Ramp ($B)", "content": { "type": "chart", "series": [ { "data": [ 0, 0.5, 5.2, 11.5, 16, 19, 21, 22 ], "name": "Mounjaro (T2D)" }, { "data": [ 0, 0, 0.2, 5, 12, 18, 24, 28 ], "name": "Zepbound (obesity)" }, { "data": [ 0, 0, 0, 0, 0, 1, 5, 10 ], "name": "Retatrutide (est.)" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E", "2028E" ], "gridBottom": 80, "showLineValues": false }, "_headerMaxChars": 35 }, { "span": 6, "header": "Lilly Pipeline Beyond GLP-1", "content": { "data": { "rows": [ [ "Donanemab", "Alzheimer's", "Approved", "~$5-7B" ], [ "Retatrutide", "Obesity", "Phase 3", "~$15B+" ], [ "Lebrikizumab", "Atopic derm.", "Approved", "~$3B" ], [ "Jaypirca", "B-cell malign.", "Approved", "~$2B" ], [ "Orforglipron", "Obesity (oral)", "Phase 3", "~$5B+" ] ], "headers": [ "Asset", "Indication", "Stage", "Peak Sales Est." ], "fontSize": 900, "colWidths": [ 4, 4, 3, 4 ], "rowHeight": 0.27, "_cellMaxChars": [ 14, 14, 10, 14 ], "_headersMaxChars": [ 28, 28, 20, 28 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "Financial Strength", "content": { "type": "statGrid", "items": [ { "label": "2024 Free Cash Flow", "value": "$12B", "sublabel": "Rapidly expanding" }, { "label": "R&D Spend (2024)", "value": "$9B", "sublabel": "20% of revenue" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Key Risks", "content": { "type": "bulletList", "items": [ "IRA price negotiation: Mounjaro eligible 2026", "Valuation pricing near-perfection: >30x 2025E EPS", "Novo + Amgen competitive response in 2025-26", "Retatrutide Ph3 failure would reset obesity thesis" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 188, "_lineCount": 9, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Eli Lilly: The GLP-1 Juggernaut", "footer": "Source: Lilly 10-K 2024, Evaluate Pharma, FactSet. Market data as of Jan 2026.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 31, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Lilly Revenue Composition 2024 vs. 2028E ($B)", "content": { "type": "chart", "series": [ { "data": [ 0.5, 5.4, 16.5, 28, 37, 52 ], "name": "Incretin portfolio" }, { "data": [ 5, 5.5, 6.5, 7.5, 8.5, 11 ], "name": "Oncology / immunology" }, { "data": [ 0.5, 0.5, 1, 2, 4, 7 ], "name": "Neuro (donanemab+)" }, { "data": [ 22.5, 17, 21, 19, 18, 16 ], "name": "Legacy / other" } ], "stacked": true, "chartType": "bar", "categories": [ "2022A", "2023A", "2024A", "2025E", "2026E", "2028E" ], "gridBottom": 80, "horizontal": false, "showBarValues": false }, "_headerMaxChars": 52 }, { "span": 6, "header": "Strategic Priorities: What Lilly Does Next", "content": { "data": { "rows": [ [ "Oral GLP-1", "Orforglipron Ph3 readout", "2025-26", "Unlocks inj-averse pts" ], [ "Retatrutide Ph3", "Triple agonist obesity data", "2026", "New ceiling; pricing power" ], [ "IRA mitigation", "New formulations, devices", "Ongoing", "Protect Mounjaro revenue" ], [ "M&A", "Oncology & neuro bolt-ons", "2025-27", "Diversify beyond GLP-1" ], [ "Manufacturing", "$5.5B capex ramp", "2025-26", "Remove supply constraint" ] ], "headers": [ "Priority", "Action", "Timeline", "Implication" ], "fontSize": 900, "colWidths": [ 3, 5, 2, 5 ], "rowHeight": 0.27, "_cellMaxChars": [ 15, 28, 9, 28 ], "_headersMaxChars": [ 30, 56, 18, 56 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Lilly vs. Novo: Head-to-Head", "content": { "data": { "rows": [ [ "Weight loss", "~20% (tirz)", "~15% (sema)" ], [ "CV outcomes", "Pending 2026", "SELECT done" ], [ "Oral option", "Orforglipron", "Rybelsus/Amyc." ], [ "Valuation", "~30x EPS", "~25x EPS" ], [ "Next-gen", "Retatrutide", "CagriSema" ] ], "headers": [ "Dimension", "Lilly", "Novo" ], "fontSize": 900, "colWidths": [ 4, 4, 4 ], "rowHeight": 0.16, "_cellMaxChars": [ 19, 19, 19 ], "_headersMaxChars": [ 38, 38, 38 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 36 }, { "span": 6, "header": "Our View", "content": { "type": "bulletList", "items": [ "Lilly is executing one of the greatest pharmaceutical pivots in history \u2014 from mid-tier to largest pharma by market cap in under a decade", "The bull case is underappreciated: oral GLP-1 + retatrutide + donanemab together could sustain $100B+ revenue by 2030", "Primary risk is valuation, not fundamentals \u2014 the stock prices a lot of good news; any trial failure triggers sharp de-rating", "Best owned as a core position with size reduced on any significant appreciation from current levels" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 478, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Eli Lilly: Strategic Outlook & View", "footer": "Source: Lilly investor day 2024, SVB Leerink, Evaluate Pharma. Views are analytical.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 35, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$500B", "sublabel": "Largest European company" }, { "label": "2024 Revenue", "value": "~$33B", "sublabel": "+25% YoY" }, { "label": "Ozempic Revenue", "value": "$14.3B", "sublabel": "T2D & cardiovascular" }, { "label": "Wegovy Revenue", "value": "$6.8B", "sublabel": "Obesity; supply-constrained" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "Why Novo Still Wins", "content": { "type": "bulletList", "items": [ "SELECT CV trial \u2014 only MACE data for GLP-1; payer gold standard", "First-mover formulary position; embedded in payer rebate structures", "CagriSema Phase 3: muscle-preservation advantage over pure GLP-1s", "Oral semaglutide expanding; oral pipeline for next-gen wave", "Denmark infrastructure: 50%+ global insulin supply \u2014 regulatory moat" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 322, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 78 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Semaglutide Portfolio Revenue ($B)", "content": { "type": "chart", "series": [ { "data": [ 2.1, 3.8, 6.2, 9.1, 13.9, 14.3, 15, 15.5, 15 ], "name": "Ozempic (T2D)" }, { "data": [ 0, 0.1, 0.3, 0.9, 2.2, 6.8, 11, 15, 18 ], "name": "Wegovy (obesity)" }, { "data": [ 0.1, 0.5, 1.1, 1.7, 2.1, 2.8, 3.5, 4.2, 5 ], "name": "Rybelsus (oral)" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2019", "2020", "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E" ], "gridBottom": 80, "showLineValues": false }, "_headerMaxChars": 35 }, { "span": 6, "header": "Pipeline Beyond Semaglutide", "content": { "data": { "rows": [ [ "CagriSema", "GLP-1+amylin", "Ph3", "~25%+muscle" ], [ "Amycretin", "GLP-1/amyl or.", "Ph2", "First oral combo" ], [ "IcoSema", "Insulin/sema", "Ph3", "T2D simplification" ], [ "NNC0479", "GLP-1/GIP", "Ph1", "Vs. Lilly" ], [ "Sema FLOW", "Renal outcomes", "Filed", "CKD $15B+ mkt" ] ], "headers": [ "Asset", "Mechanism", "Stage", "Upside" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 5 ], "rowHeight": 0.25, "_cellMaxChars": [ 14, 14, 5, 19 ], "_headersMaxChars": [ 28, 28, 10, 38 ] }, "type": "table", "_maxRows": 8, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "Financial Strength", "content": { "type": "statGrid", "items": [ { "label": "Operating Margin", "value": "45%+", "sublabel": "Best in class" }, { "label": "R&D Spend (2024)", "value": "~$7B", "sublabel": "21% of revenue" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Key Risks", "content": { "type": "bulletList", "items": [ "CagriSema Ph3 miss would cede next-gen to Lilly", "Wegovy supply: any disruption hits stock hard", "IRA: semaglutide negotiation target by 2026", "Lilly closing efficacy gap faster than expected" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 182, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Novo Nordisk: The GLP-1 Originator", "footer": "Source: Novo Nordisk Annual Report 2024, Evaluate Pharma, FactSet. Data as of Jan 2026.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 34, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Novo Revenue Bridge 2024-2028E ($B)", "content": { "type": "chart", "series": [ { "data": [ 9.1, 13.9, 14.3, 15, 15.5, 14 ], "name": "Ozempic / semaglutide T2D" }, { "data": [ 0.9, 2.2, 6.8, 11, 15, 22 ], "name": "Wegovy obesity" }, { "data": [ 0, 0, 0, 0.5, 2, 8 ], "name": "CagriSema / next-gen" }, { "data": [ 5, 5.5, 6, 6.5, 7, 9 ], "name": "Rare disease / other" } ], "stacked": true, "chartType": "bar", "categories": [ "2022A", "2023A", "2024A", "2025E", "2026E", "2028E" ], "gridBottom": 80, "showBarValues": false }, "_headerMaxChars": 52 }, { "span": 6, "header": "Novo's Expansion Strategy: Beyond GLP-1", "content": { "data": { "rows": [ [ "Rare disease", "Cardior, Forma acq.", "Integrated", "Hematology diversif." ], [ "CNS", "GLP-1 CNS trials", "Ph2 exploratory", "Addiction/Parkinson upside" ], [ "NASH/MASH", "Sema NASH filing", "Filed", "Vs. Madrigal Rezdiffra" ], [ "CKD", "FLOW renal outcomes", "Filed", "New large indication" ], [ "Oral pipeline", "Amycretin Ph2", "Phase 2", "First oral GLP-1+amylin" ] ], "headers": [ "Area", "Asset/Move", "Status", "Why It Matters" ], "fontSize": 900, "colWidths": [ 3, 4, 3, 5 ], "rowHeight": 0.27, "_cellMaxChars": [ 15, 22, 15, 28 ], "_headersMaxChars": [ 30, 44, 30, 56 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Competitive Positioning vs. Lilly", "content": { "data": { "rows": [ [ "CV outcomes", "SELECT done", "Lilly data coming" ], [ "Oral GLP-1", "Rybelsus appr.", "Orforglipron stronger" ], [ "Payer access", "Entrenched", "Lilly gaining share" ], [ "Efficacy", "15% wt loss", "Tirz at 20%+" ], [ "Next-gen", "CagriSema", "Retatrutide leads" ] ], "headers": [ "Factor", "Novo Edge", "Novo Risk" ], "fontSize": 900, "colWidths": [ 3, 4, 5 ], "rowHeight": 0.17, "_cellMaxChars": [ 13, 19, 25 ], "_headersMaxChars": [ 26, 38, 50 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 36 }, { "span": 6, "header": "Our View", "content": { "type": "bulletList", "items": [ "Novo is the more defensive GLP-1 play \u2014 SELECT CV outcomes data and payer entrenchment create a durable floor under revenue", "CagriSema is the key catalyst: if Phase 3 delivers 25%+ weight loss with muscle preservation, Novo reclaims the efficacy crown", "The bear case is not losing to Lilly \u2014 it's the IRA and supply disruption compressing both revenue and multiple simultaneously", "Best owned as a pair trade with Lilly: lower valuation, more CV/payer protection, slightly lower growth ceiling" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 486, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Novo Nordisk: Beyond Obesity", "footer": "Source: Novo Nordisk investor day 2024, Evaluate Pharma, SVB Leerink. Views analytical.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 28, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$250B", "sublabel": "As of Jan 2026" }, { "label": "2024 Revenue", "value": "$54.1B", "sublabel": "+18% YoY" }, { "label": "Oncology Revenue", "value": "$21.2B", "sublabel": "Largest franchise" }, { "label": "GLP-1 Program", "value": "AZD5004", "sublabel": "Oral; Phase 2" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "AZ's GLP-1 Thesis", "content": { "type": "bulletList", "items": [ "AZ targets oral small-molecule GLP-1s vs IV leaders", "AZD5004: once-daily oral with differentiated PK vs Pfizer's danuglipron", "MASH/NASH is key GLP-1 opportunity with FXR/PPAR pipeline synergy", "Ampio acquisition + Gracell licensing = platform builder strategy", "Cardiometabolic + oncology: GLP-1 supports Tagrisso co-prescription" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 319, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 78 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "AZ Revenue by Franchise 2024 ($B)", "content": { "type": "chart", "series": [ { "data": [ 21.2, 12.5, 9.3, 7.4, 3.7 ], "name": "Revenue ($B)" } ], "barColor": "#4472C4", "gridLeft": 110, "chartType": "bar", "categories": [ "Oncology", "CVRM", "Rare Disease", "Resp./Immunol.", "Vaccines" ], "gridBottom": 20, "horizontal": true, "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 35 }, { "span": 6, "header": "GLP-1 & Metabolic Pipeline", "content": { "data": { "rows": [ [ "AZD5004", "Oral GLP-1 SM", "Ph2", "QD tolerable" ], [ "AZD6234", "GLP-1/GIP oral", "Ph1", "Combo oral next-gen" ], [ "MASH combo", "GLP-1+lanif.", "Ph2", "Liver disease diff." ], [ "AZD9550", "Amylin analog", "Pre.", "Muscle-preserving" ], [ "Farxiga", "SGLT2 (CKD)", "Appr.", "CKD outcomes study" ] ], "headers": [ "Asset", "Mechanism", "Stage", "Differentiation" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 5 ], "rowHeight": 0.25, "_cellMaxChars": [ 14, 14, 5, 19 ], "_headersMaxChars": [ 28, 28, 10, 38 ] }, "type": "table", "_maxRows": 8, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "Financial Profile", "content": { "type": "statGrid", "items": [ { "label": "R&D Investment", "value": "$10.0B", "sublabel": "18% of revenue" }, { "label": "M&A Firepower", "value": "~$35B", "sublabel": "Post-Rare Disease build" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Key Risks", "content": { "type": "bulletList", "items": [ "AZD5004 Phase 2 data disappointing vs. danuglipron", "Tagrisso LOE 2026 \u2014 $5.5B revenue at risk", "GLP-1 entry is late; scale vs. Lilly/Novo is a real barrier", "MASH space getting crowded: Madrigal, Novo, Lilly all competing" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 213, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "AstraZeneca: GLP-1 Challenger Strategy", "footer": "Source: AstraZeneca Annual Report 2024, Evaluate Pharma, FactSet. Data as of Jan 2026.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "AZ Revenue Trajectory 2022-2028E ($B)", "content": { "type": "chart", "series": [ { "data": [ 37.4, 44.4, 45.8, 54.1, 60, 63, 68, 74 ], "name": "Total Revenue" }, { "data": [ 14.6, 16.4, 17.2, 21.2, 24, 25, 27, 29 ], "name": "Oncology" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E", "2028E" ], "gridBottom": 60, "showLineValues": false }, "_headerMaxChars": 52 }, { "span": 6, "header": "AZ's Strategic Priorities in GLP-1 Era", "content": { "data": { "rows": [ [ "Oral GLP-1 diff.", "AZD5004 must show >=10% with tolerability", "2025 Ph2" ], [ "MASH combo strategy", "GLP-1+FXR proven combo; AZ has both", "2026 Ph2/3" ], [ "Tagrisso lifecycle", "3rd-gen EGFR combos to extend pre-LOE", "2025-2026" ], [ "ADC expansion", "Post-Daiichi; building ADC pipeline", "Ongoing" ], [ "Rare disease defense", "Alexion assets sustain margin", "Ongoing" ] ], "headers": [ "Priority", "Rationale", "Timeframe" ], "fontSize": 900, "colWidths": [ 4, 7, 3 ], "rowHeight": 0.27, "_cellMaxChars": [ 24, 44, 17 ], "_headersMaxChars": [ 48, 88, 34 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "GLP-1 Positioning vs. Leaders", "content": { "data": { "rows": [ [ "Entry strategy", "Oral SM, not injectable" ], [ "Target market", "GLP-1 naive; inj-averse" ], [ "Combination", "MASH + cardiometa combo" ], [ "Scale vs. Lilly", "Meaningfully smaller" ], [ "Timeline", "2-3 yrs behind leaders" ] ], "headers": [ "Factor", "AZ Position" ], "fontSize": 900, "colWidths": [ 5, 7 ], "rowHeight": 0.17, "_cellMaxChars": [ 25, 36 ], "_headersMaxChars": [ 50, 72 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 36 }, { "span": 6, "header": "Our View", "content": { "type": "bulletList", "items": [ "AZ angle: oral SM + MASH, not injectable vs. Lilly/Novo", "AZD5004 Ph2 mid-2025: clean tolerability = partnership or Ph3", "Platform: GLP-1 complements Farxiga CKD and Tagrisso franchise", "Watch for GLP-1 acquisition (Zealand? Structure Tx?) to accelerate" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 244, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "AstraZeneca: GLP-1 Strategic Outlook", "footer": "Source: AZ investor day 2024, Evaluate Pharma, SVB Leerink. Views are analytical.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 36, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$145B", "sublabel": "Down 60% from 2022 peak" }, { "label": "2024 Revenue", "value": "$63.6B", "sublabel": "-41% from COVID peak" }, { "label": "Danuglipron", "value": "Ph 2b", "sublabel": "Oral GLP-1; QD dosing" }, { "label": "Cost Cuts", "value": "$4B+", "sublabel": "Restructuring through 2025" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "Pfizer's GLP-1 Situation", "content": { "type": "bulletList", "items": [ "Danuglipron is once-daily oral GLP-1 targeting injection-averse patients", "Earlier BID discontinued due to GI issues; QD is make-or-break program", "Success puts Pfizer ahead of AZ in oral GLP-1 \u2014 first QD with weight loss", "Other reset levers: Seagen ADCs, RSV vaccine Abrysvo, Nurtec migraine", "Post-COVID drop brutal: $63B in 2024 vs $100B in 2022 \u2014 urgency existential" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 359, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 78 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Pfizer: COVID to Recovery ($B)", "content": { "type": "chart", "series": [ { "data": [ 51.8, 41.9, 81.3, 100.3, 58.5, 63.6, 65, 70, 76 ], "name": "Total Revenue" }, { "data": [ 51.8, 41.9, 45, 52, 58.5, 63.6, 65, 70, 76 ], "name": "Ex-COVID" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2019", "2020", "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E" ], "gridBottom": 60, "showLineValues": false }, "_headerMaxChars": 35 }, { "span": 6, "header": "Non-COVID Pipeline: Key Assets", "content": { "data": { "rows": [ [ "Danuglipron", "Obesity (oral)", "Phase 2b", "~$6-10B" ], [ "Padcev", "Bladder cancer", "Approved", "~$4B" ], [ "Adcetris", "Lymphoma", "Approved", "~$2.5B" ], [ "Elranatamab", "Myeloma", "Approved", "~$2B" ], [ "Abrysvo", "RSV vaccine", "Approved", "~$2-3B" ] ], "headers": [ "Asset", "Indication", "Stage", "Peak Sales Est." ], "fontSize": 900, "colWidths": [ 4, 4, 3, 4 ], "rowHeight": 0.27, "_cellMaxChars": [ 14, 14, 10, 14 ], "_headersMaxChars": [ 28, 28, 20, 28 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "Financial Position", "content": { "type": "statGrid", "items": [ { "label": "Net Debt", "value": "~$35B", "sublabel": "Post-Seagen; elevated" }, { "label": "FCF (2024)", "value": "~$12B", "sublabel": "Rebounding post-COVID" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Key Risks", "content": { "type": "bulletList", "items": [ "Danuglipron QD tolerability data \u2014 must be cleaner than BID", "Seagen integration: $43B deal must deliver pipeline value", "Eliquis LOE 2026: $12B revenue at risk", "COVID revenue overhang suppressing multiple re-rating" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 207, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Pfizer: Oral GLP-1 Bet & COVID Reset", "footer": "Source: Pfizer 10-K 2024, Evaluate Pharma, FactSet. Market data as of Jan 2026.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 36, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Pfizer Revenue Bridge: COVID to New Base ($B)", "content": { "type": "chart", "series": [ { "data": [ 56.7, 12.5, 8, 6, 4, 2 ], "name": "COVID (Paxlovid + vaccine)" }, { "data": [ 0, 0, 4.5, 7, 9, 14 ], "name": "Seagen ADC portfolio" }, { "data": [ 13, 14, 15, 16, 17, 20 ], "name": "Oncology / hospital" }, { "data": [ 30.6, 32, 36.1, 36, 34, 32 ], "name": "Primary care / other" } ], "stacked": true, "chartType": "bar", "categories": [ "2022A", "2023A", "2024A", "2025E", "2026E", "2028E" ], "gridBottom": 80, "showBarValues": false }, "_headerMaxChars": 52 }, { "span": 6, "header": "Pfizer's Strategic Reset Plan", "content": { "data": { "rows": [ [ "ADC build-out", "Seagen integr. + ADCs", "Underway", "+$5-8B by 2027" ], [ "Oral GLP-1", "Danuglipron QD Ph2b data", "2025 read", "+$6-10B if success" ], [ "Cost reduction", "$4B+ in structural savings", "~Complete", "Margin to 35%+" ], [ "Eliquis LOE", "New formulations", "Ongoing", "Partial offset" ], [ "M&A", "Distressed mid-cap targets", "Active", "Pipeline refill" ] ], "headers": [ "Lever", "Action", "Status", "Revenue Impact" ], "fontSize": 900, "colWidths": [ 3, 5, 3, 4 ], "rowHeight": 0.27, "_cellMaxChars": [ 15, 28, 15, 22 ], "_headersMaxChars": [ 30, 56, 30, 44 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Danuglipron: What We Need to See", "content": { "data": { "rows": [ [ "Weight loss", ">=10% vs. placebo" ], [ "GI tolerability", "Nausea rate <20%" ], [ "Dose frequency", "Once-daily confirmed" ], [ "CV safety", "No QTc signal" ], [ "vs. BID", "Clearly superior PK" ] ], "headers": [ "Metric", "Bar to Clear" ], "fontSize": 900, "colWidths": [ 5, 7 ], "rowHeight": 0.17, "_cellMaxChars": [ 25, 36 ], "_headersMaxChars": [ 50, 72 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 36 }, { "span": 6, "header": "Our View", "content": { "type": "bulletList", "items": [ "Pfizer is the most asymmetric GLP-1 story: the stock prices almost no value for danuglipron \u2014 positive Phase 2b data would be a significant catalyst", "The post-COVID reset is real but largely complete; the base business at $63B is more durable than the market prices given Seagen ADC momentum", "Danuglipron is binary \u2014 if QD tolerability is clean, Pfizer is positioned as the first truly accessible oral GLP-1 challenger ahead of orforglipron", "Best owned as a value/event-driven position: cheap on pipeline-adjusted basis, with a clear near-term catalyst in mid-2025" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 558, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Pfizer: Can the Giant Rebuild?", "footer": "Source: Pfizer investor day 2024, SVB Leerink, Evaluate Pharma. Views are analytical.", "sectionLabel": "GLP-1 WARS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 30, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "5." } ], "text": "5.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "CHINA'S RISE", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 12, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772025059914-6a0c105d7ea2.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#2F5496" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 5, "children": [ { "span": 6, "header": "China Innovation Scale", "content": { "type": "statGrid", "items": [ { "label": "In Bispecific Antibodies Globally", "value": "#1", "sublabel": "Pipeline programs" }, { "label": "ADC Developer Globally", "value": "Top 3", "sublabel": "BioNTech, HUTCHMED, Zymeworks" }, { "label": "GLP-1 Global Pipeline Share", "value": "40%+", "sublabel": "ClinicalTrials data" }, { "label": "Outbound Licensing 2023\u201324", "value": "$15B+", "sublabel": "Western pharma buying" } ] }, "_headerMaxChars": 36 }, { "span": 6, "header": "My Contrarian View on China", "content": { "type": "bulletList", "items": [ "Most US investors see China through a geopolitical risk lens \u2014 they're missing the science", "China's ADC programs are at least as good as Western counterparts \u2014 often faster and cheaper to develop", "The out-licensing wave is accelerating: AZ, Pfizer, BMS all actively sourcing from China", "BIOSECURE Act risk is overstated for non-manufacturing partnerships", "Best opportunity: licensing deals where clinical risk is largely de-risked by Phase 2 China data" ], "fontSize": 1000, "_maxChars": 588, "_maxLines": 12, "_overflow": false, "_charCount": 444, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 49, "_maxCharsPerItem": 98 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 34 } ], "direction": "col" }, { "span": 7, "children": [ { "span": 6, "header": "Notable China \u2192 West Licensing Deals (2023\u20132025)", "content": { "data": { "rows": [ [ "LaNova Medicines", "Pfizer", "CLDN18.2 ADC", "$6.1B" ], [ "Zymeworks", "J&J", "HER2 bisp. ADC", "$1.7B" ], [ "Akeso (HK)", "Summit Tx", "Ivonescimab", "$5.0B" ], [ "Kelun-Biotech", "Merck", "HER3 ADC", "$1.4B" ] ], "headers": [ "Chinese Partner", "Western Licensee", "Asset", "Value" ], "fontSize": 900, "colWidths": [ 3, 3, 3, 3 ], "rowHeight": 0.32, "_cellMaxChars": [ 20, 20, 20, 20 ], "_headersMaxChars": [ 40, 40, 40, 40 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 4 }, "_headerMaxChars": 52 }, { "span": 6, "header": "China Modality Leadership", "content": { "type": "chart", "series": [ { "data": [ 320, 185, 280, 95, 62 ], "name": "China Pipeline Programs" }, { "data": [ 190, 290, 430, 180, 250 ], "name": "Rest of World Programs" } ], "stacked": false, "chartType": "bar", "categories": [ "Bispecific Ab", "ADCs", "GLP-1/Metabolic", "CAR-T", "mRNA" ], "gridBottom": 45, "horizontal": true }, "_headerMaxChars": 52 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "China: A Genuine Biopharma Superpower", "footer": "Source: Evaluate Pharma China Strategic Playbook, Jan 2026; ClinicalTrials.gov; Company filings", "sectionLabel": "CHINA'S RISE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 37, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 6, "children": [ { "span": 6, "header": "China vs. RoW: Pipeline Programs by Modality", "content": { "type": "chart", "series": [ { "data": [ 320, 185, 280, 95, 110, 48, 140, 62 ], "name": "China" }, { "data": [ 190, 290, 430, 45, 380, 12, 220, 35 ], "name": "Rest of World" } ], "stacked": false, "gridLeft": 110, "chartType": "bar", "categories": [ "Bispecific Ab", "ADC", "GLP-1/Metabolic", "CAR-T (solid)", "PD-1/L1", "CLDN18.2", "HER2-targeted", "Oral GLP-1 SM" ], "gridBottom": 60, "horizontal": true, "showBarValues": false }, "_headerMaxChars": 44 }, { "span": 6, "header": "China's Structural Innovation Advantages", "content": { "type": "bulletList", "items": [ "Patient enrollment speed: Chinese Phase 2 trials enroll 3-5x faster than US equivalents \u2014 data arrives earlier", "Cost of development: Phase 2 oncology trials cost ~40-60% less in China; same FDA-applicable endpoints", "NMPA approval as bridge: domestic approval de-risks global licensing \u2014 Western pharma buying post-NMPA data", "Bispecific engineering depth: China leads in CD3/tumor bispecifics, PD-1/VEGF combos, and CLDN18.2 programs", "ADC chemistry: Kelun, RemeGen, and KLUS have pioneered novel linker-payload combinations now in-licensed globally" ], "fontSize": 1000, "_maxChars": 832, "_maxLines": 13, "_overflow": false, "_charCount": 539, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 128 }, "_headerMaxChars": 44 } ], "direction": "col" }, { "span": 6, "children": [ { "span": 6, "header": "China Out-Licensing Deal Flow ($B total)", "content": { "type": "chart", "series": [ { "data": [ 0.3, 0.5, 0.9, 1.4, 3.2, 5.8, 7.5 ], "name": "Upfront ($B)" }, { "data": [ 0.8, 1.2, 2.1, 3.5, 8.5, 18, 22 ], "name": "Milestones ($B)" } ], "stacked": true, "chartType": "bar", "categories": [ "2019", "2020", "2021", "2022", "2023", "2024", "2025E" ], "gridBottom": 60, "showBarValues": false }, "_headerMaxChars": 44 }, { "span": 6, "header": "Where China Has Global Leadership", "content": { "data": { "rows": [ [ "Bispecific Ab", "#1 globally", "Akeso, Zymeworks", "Summit $5B Akeso" ], [ "PD-1/VEGF combo", "Only apprvd", "Akeso (AK112)", "AZ evaluating" ], [ "CLDN18.2 ADC", "3 in late", "LaNova, KLUS", "Pfizer $6.1B" ], [ "HER3 ADC", "Most progs", "Kelun, RemeGen", "Merck $1.4B" ], [ "Oral GLP-1 SM", "40%+ pipe", "Inventisbio, Sci.", "AZ/Pfizer watch" ], [ "CAR-T (solid)", "Most Ph1/2", "Gracell, IASO", "AZ $1.2B Gracell" ] ], "headers": [ "Area", "China Lead", "Key Companies", "Western Signal" ], "fontSize": 900, "colWidths": [ 4, 3, 5, 5 ], "rowHeight": 0.26, "_cellMaxChars": [ 16, 11, 20, 20 ], "_headersMaxChars": [ 32, 22, 40, 40 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 6 }, "_headerMaxChars": 44 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Where China Is Winning: Innovation Map", "footer": "Source: Evaluate Pharma, ClinicalTrials.gov, GlobalData, NMPA filings, Jan 2026.", "sectionLabel": "CHINA'S RISE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap (NASDAQ)", "value": "~$18B", "sublabel": "Dual-listed HK + US" }, { "label": "2024 Revenue", "value": "$3.8B", "sublabel": "+26% YoY" }, { "label": "Brukinsa (BTK)", "value": "$2.6B", "sublabel": "Approved US, EU, CN" }, { "label": "Pipeline Assets", "value": "50+", "sublabel": "Globally active" } ] }, "_headerMaxChars": 28 }, { "span": 6, "header": "Why BeiGene Is Different", "content": { "type": "bulletList", "items": [ "Only Chinese biotech with fully commercialized US oncology \u2014 Brukinsa taking share from ibrutinib", "ALPINE trial showed superiority over ibrutinib in CLL \u2014 a best-in-class claim", "Global infrastructure: 10,000+ employees, US/EU commercial teams, FDA manufacturing", "Tislelizumab (PD-1) partnered with Novartis globally; BeiGene retains China rights" ], "fontSize": 1000, "_maxChars": 507, "_maxLines": 13, "_overflow": false, "_charCount": 339, "_lineCount": 12, "lineSpacing": 0.9, "_charsPerLine": 39, "_maxCharsPerItem": 117 }, "_headerMaxChars": 28 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "Brukinsa Revenue vs. Ibrutinib ($B)", "content": { "type": "chart", "series": [ { "data": [ 0.1, 0.2, 0.7, 1.5, 2.6, 3.8, 5, 6.5 ], "name": "Brukinsa (BeiGene)" }, { "data": [ 4.7, 5.3, 5.9, 5.1, 4.2, 3.5, 2.9, 2.4 ], "name": "Imbruvica (ibrutinib)" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2020", "2021", "2022", "2023", "2024", "2025E", "2026E", "2027E" ], "gridBottom": 60, "showLineValues": false }, "_headerMaxChars": 35 }, { "span": 6, "header": "Key Pipeline Beyond Brukinsa", "content": { "data": { "rows": [ [ "Tislelizumab", "PD-1", "Apprvd CN", "Multiple cancers" ], [ "BGB-11417", "BCL2", "Phase 3", "CLL / AML" ], [ "BGB-16673", "BTK CDAC", "Phase 2", "B-cell malign." ], [ "Sonrotoclax", "BCL2", "Phase 3", "Hematology" ], [ "BGB-A317", "TIGIT/PD-1", "Phase 2", "Solid tumors" ] ], "headers": [ "Asset", "Target", "Stage", "Indication" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 5 ], "rowHeight": 0.27, "_cellMaxChars": [ 14, 10, 10, 19 ], "_headersMaxChars": [ 28, 20, 20, 38 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 35 } ], "direction": "col" }, { "span": 3, "children": [ { "span": 6, "header": "Financial Profile", "content": { "type": "statGrid", "items": [ { "label": "Cash Position", "value": "$4.2B", "sublabel": "Well-funded through 2027" }, { "label": "R&D Spend (2024)", "value": "$1.9B", "sublabel": "50% of revenue" } ] }, "_headerMaxChars": 20 }, { "span": 6, "header": "Our View", "content": { "type": "bulletList", "items": [ "BeiGene proves Chinese biotechs can build global franchises", "Brukinsa crossing $5B by 2026 makes it a blockbuster", "Risk: geopolitical tension and BIOSECURE Act weigh on multiple", "M&A gets commercial oncology platform plus 50+ pipeline assets" ], "fontSize": 1000, "_maxChars": 351, "_maxLines": 13, "_overflow": false, "_charCount": 235, "_lineCount": 11, "lineSpacing": 0.9, "_charsPerLine": 27, "_maxCharsPerItem": 81 }, "_headerMaxChars": 20 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "BeiGene: China's Global Oncology Platform", "footer": "Source: BeiGene 20-F 2024, Evaluate Pharma, FactSet. Market data as of Jan 2026.", "sectionLabel": "CHINA'S RISE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 41, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 6, "children": [ { "span": 5, "children": [ { "span": 6, "header": "Akeso Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap (HK)", "value": "~$8B", "sublabel": "HK-listed" }, { "label": "AK112 deal (Summit)", "value": "$5.0B", "sublabel": "PD-1/VEGF bispecific" }, { "label": "US IND filed", "value": "2024", "sublabel": "Ivonescimab Ph3 global" } ] }, "_headerMaxChars": 36 }, { "span": 6, "content": { "type": "bulletList", "items": [ "AK112: PD-1/VEGF bispecific \u2014 unique dual checkpoint+anti-angio", "Phase 3 CN: superior PFS vs. pembrolizumab in NSCLC", "Summit licensed ex-CN for $5B; global Ph3 in US/EU/JP", "Replication of CN data = $10B+ asset; direct Keytruda threat" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 227, "_lineCount": 7, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 } } ], "direction": "col" }, { "span": 7, "header": "Akeso Pipeline", "content": { "data": { "rows": [ [ "AK112 (ivonescimab)", "PD-1/VEGF bispfc", "Approved", "Phase 3", "Summit $5B" ], [ "AK101", "IL-12/23", "Phase 3", "Phase 2", "In-house" ], [ "AK104", "PD-1/CTLA-4", "Approved", "Phase 2", "In-house" ], [ "AK117", "CD47 mAb", "Phase 2", "Phase 1", "In-house" ], [ "AK129", "IL-2/PD-1 bispfc", "Phase 1", "Preclin.", "In-house" ] ], "headers": [ "Asset", "Mechanism", "Stage CN", "Stage Global", "Deal" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3, 3 ], "rowHeight": 0.26, "_cellMaxChars": [ 20, 20, 8, 14, 14 ], "_headersMaxChars": [ 40, 40, 16, 28, 28 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 5, "children": [ { "span": 6, "header": "LaNova Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Status", "value": "Private", "sublabel": "VC-backed; pre-IPO" }, { "label": "Pfizer deal (2024)", "value": "$6.1B", "sublabel": "CLDN18.2 ADC" }, { "label": "Lead asset stage", "value": "Phase 2", "sublabel": "CN + US IND filed" } ] }, "_headerMaxChars": 36 }, { "span": 6, "content": { "type": "bulletList", "items": [ "LM-302: CLDN18.2 ADC \u2014 hottest gastric cancer target", "Pfizer paid $6.1B for ex-CN rights to a Ph2 asset", "Validates CN ADC chemistry; linker-payload vs. Daiichi", "Pre-IPO HK/US listing 2025-26; Pfizer deal = valuation anchor" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 216, "_lineCount": 6, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 } } ], "direction": "col" }, { "span": 7, "header": "CLDN18.2 Competitive Landscape", "content": { "data": { "rows": [ [ "LaNova (CN)", "LM-302", "ADC", "Phase 2", "Pfizer $6.1B" ], [ "Zymeworks (CA)", "ZW49", "HER2 bispfc ADC", "Phase 2", "J&J $1.7B" ], [ "KLUS Pharma", "KL264", "ADC", "Phase 1", "Undisclosed" ], [ "Astellas", "Zolbetuximab", "mAb", "Approved", "Commercial" ], [ "Sotio", "SOT102", "ADC", "Phase 1", "In-house" ] ], "headers": [ "Company", "Asset", "Modality", "Stage", "Partner" ], "fontSize": 900, "colWidths": [ 4, 3, 4, 2, 4 ], "rowHeight": 0.26, "_cellMaxChars": [ 19, 13, 19, 8, 19 ], "_headersMaxChars": [ 38, 26, 38, 16, 38 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Akeso & LaNova: Bispecific & ADC Leaders", "footer": "Source: Akeso HK filings, LaNova press releases, Evaluate Pharma, FactSet Jan 2026.", "sectionLabel": "CHINA'S RISE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 40, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 6, "children": [ { "span": 5, "children": [ { "span": 6, "header": "Zymeworks Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap (NYSE)", "value": "~$1.2B", "sublabel": "Canada-HK hybrid" }, { "label": "J&J deal (2023)", "value": "$1.7B", "sublabel": "HER2 bispecific ADC" }, { "label": "Lead asset", "value": "ZW220", "sublabel": "Phase 2 HER2+ gastric" } ] }, "_headerMaxChars": 36 }, { "span": 6, "content": { "type": "bulletList", "items": [ "Bispecific ADC: two tumor targets for selectivity", "ZW49 licensed to J&J $1.7B; validates the class", "ZW220 targets HER2-low, ineligible for T-DXd", "Azyp platform: modular ADC across tumor antigens" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 188, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 } } ], "direction": "col" }, { "span": 7, "header": "Zymeworks ADC Platform & Pipeline", "content": { "data": { "rows": [ [ "ZW49", "HER2 bispfc", "ADC", "Phase 2", "J&J $1.7B licensed" ], [ "ZW220", "HER2 (low)", "ADC", "Phase 2", "In-house; partnering" ], [ "ZW171", "CD3/MSLN", "Bispfc mAb", "Phase 1", "In-house" ], [ "ZW251", "HER3", "ADC", "Preclin.", "Azyp platform" ] ], "headers": [ "Asset", "Target", "Modality", "Stage", "Status" ], "fontSize": 900, "colWidths": [ 3, 3, 3, 2, 6 ], "rowHeight": 0.26, "_cellMaxChars": [ 13, 13, 13, 8, 30 ], "_headersMaxChars": [ 26, 26, 26, 16, 60 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 4 }, "_headerMaxChars": 52 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 5, "children": [ { "span": 6, "header": "Kelun-Biotech Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap (HK)", "value": "~$3.5B", "sublabel": "Subsidiary of Kelun Pharma" }, { "label": "Merck deal (2023)", "value": "$1.4B", "sublabel": "HER3-DXd ADC" }, { "label": "ADC programs", "value": "12+", "sublabel": "Broadest CN ADC pipeline" } ] }, "_headerMaxChars": 36 }, { "span": 6, "content": { "type": "bulletList", "items": [ "Broadest CN ADC pipeline: 12+ programs, novel", "SKB264 (Trop-2): Ph3 vs. Gilead Trodelvy in TNBC", "A166 (HER3 ADC) licensed to Merck for $1.4B", "Camptothecin payloads: distinct from DXd mechanism" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 186, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 } } ], "direction": "col" }, { "span": 7, "header": "Kelun-Biotech ADC Pipeline", "content": { "data": { "rows": [ [ "SKB264", "Trop-2", "Belotecan", "Phase 3", "In-house (global)" ], [ "A166", "HER3", "DM4", "Phase 2", "Merck $1.4B" ], [ "KL264", "CLDN18.2", "Camptothecin", "Phase 1", "In-house" ], [ "KL516", "HER2", "Novel", "Phase 1", "In-house" ], [ "KL525", "Trop-2/HER3", "Bispec ADC", "Preclin.", "Novel platform" ] ], "headers": [ "Asset", "Target", "Payload", "Stage", "Partner" ], "fontSize": 900, "colWidths": [ 3, 3, 3, 2, 6 ], "rowHeight": 0.26, "_cellMaxChars": [ 13, 13, 13, 8, 30 ], "_headersMaxChars": [ 26, 26, 26, 16, 60 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Zymeworks & Kelun-Biotech: ADC Innovators", "footer": "Source: Zymeworks 20-F, Kelun-Biotech HK filing, Merck/J&J press releases, Evaluate Pharma Jan 2026.", "sectionLabel": "CHINA'S RISE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 41, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 6, "children": [ { "span": 5, "children": [ { "span": 7, "header": "HUTCHMED Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap (HK/NASDAQ)", "value": "~$3B", "sublabel": "Dual listed" }, { "label": "Approved oncology drugs", "value": "3", "sublabel": "CN approved; 1 US filed" }, { "label": "Fruquintinib (US)", "value": "Approved", "sublabel": "FDA approved Nov 2023" } ] }, "_headerMaxChars": 36 }, { "span": 5, "content": { "type": "bulletList", "items": [ "Fruquintinib: first CN small-mol FDA-approved (2023)", "Savolitinib (MET) with AstraZeneca for NSCLC globally", "Surufatinib CN-approved for NETs; US filing 2025", "Proves CN small-mol oncology can clear FDA" ], "fontSize": 1000, "_maxChars": 312, "_maxLines": 6, "_overflow": false, "_charCount": 195, "_lineCount": 5, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 } } ], "direction": "col" }, { "span": 7, "header": "HUTCHMED Global Pipeline", "content": { "data": { "rows": [ [ "Fruquintinib", "VEGFR 1/2/3", "Appr. CN", "FDA Approved", "Takeda (US/EU)" ], [ "Savolitinib", "MET", "Appr. CN", "Phase 3", "AstraZeneca" ], [ "Surufatinib", "FGFR/VEGFR", "Appr. CN", "Phase 2 US", "In-house" ], [ "HMPL-306", "IDH1/2", "Phase 2", "Phase 1 US", "In-house" ], [ "Tazemetostat", "EZH2", "Phase 2", "Phase 1", "In-house" ] ], "headers": [ "Asset", "Target", "CN Status", "Global Status", "Partner" ], "fontSize": 900, "colWidths": [ 4, 3, 2, 3, 5 ], "rowHeight": 0.26, "_cellMaxChars": [ 19, 13, 8, 13, 25 ], "_headersMaxChars": [ 38, 26, 16, 26, 50 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 5, "children": [ { "span": 6, "header": "RemeGen Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap (HK)", "value": "~$2B", "sublabel": "HK-listed" }, { "label": "Lead asset", "value": "RC48", "sublabel": "HER2 ADC; US filing 2024" }, { "label": "CN Approvals", "value": "2", "sublabel": "RC48 + Teliso-V" } ] }, "_headerMaxChars": 36 }, { "span": 6, "content": { "type": "bulletList", "items": [ "RC48: HER2 ADC approved CN; competes with DS-8201", "Pfizer partnered RC48 ex-CN via Seagen acquisition", "RC28 (VEGF/FGF bispec Ab): next-gen bispecific", "One of few CN biotechs in Western pharma portfolio" ], "fontSize": 1000, "_maxChars": 364, "_maxLines": 7, "_overflow": false, "_charCount": 195, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 52 } } ], "direction": "col" }, { "span": 7, "header": "RemeGen Pipeline & Seagen/Pfizer Partnership", "content": { "data": { "rows": [ [ "RC48 (disitamab v.)", "HER2", "ADC", "Appr. CN", "Pfizer ex-CN rights" ], [ "RC28", "VEGF/FGF", "Bispec Ab", "Phase 2", "In-house" ], [ "RC108", "c-Met", "ADC", "Phase 2", "In-house" ], [ "RC118", "CLDN18.2", "ADC", "Phase 1", "In-house" ], [ "RC148", "HER2/HER3", "Bispec ADC", "Preclin.", "Novel linker" ] ], "headers": [ "Asset", "Target", "Modality", "Stage", "Status" ], "fontSize": 900, "colWidths": [ 5, 3, 3, 2, 4 ], "rowHeight": 0.26, "_cellMaxChars": [ 25, 13, 13, 8, 19 ], "_headersMaxChars": [ 50, 26, 26, 16, 38 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "HUTCHMED & RemeGen: CN Assets Go Global", "footer": "Source: HUTCHMED Annual Report 2024, RemeGen HK filing, Seagen/Pfizer filings, Evaluate Pharma.", "sectionLabel": "CHINA'S RISE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 39, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "6." } ], "text": "6.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "FDA TURBULENCE", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 14, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772025082116-e99f3afa4024.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#4472C4" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 6, "children": [ { "span": 6, "header": "What Is Actually Happening", "content": { "type": "bulletList", "items": [ "Trump administration has installed DOGE-oriented leadership at HHS; FDA leadership in flux", "Vaccine advisory committees disrupted; some review panels suspended or restructured", "Accelerated Approval Vouchers (AAVs) creating unusual speed opportunities for some programs", "Real World Evidence (RWE) guidance being expedited for certain indications", "User fees under pressure \u2014 PDUFA VII discussions ongoing; could extend timelines" ], "fontSize": 1000, "_maxChars": 832, "_maxLines": 13, "_overflow": false, "_charCount": 418, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 128 }, "_headerMaxChars": 44 }, { "span": 6, "header": "My Read: Not as Bad as Headlines Suggest", "content": { "type": "bulletList", "items": [ "FDA career staff are largely intact \u2014 institutional knowledge preserved", "Oncology and rare disease approvals unlikely to be disrupted meaningfully", "AAV pathway could actually accelerate certain rare disease programs", "Uncertainty is creating buying opportunities in stocks with near-term PDUFA dates", "Offshore manufacturing scrutiny benefits US-based CDMOs \u2014 watch Lonza, Catalent acquirer" ], "fontSize": 1000, "_maxChars": 732, "_maxLines": 12, "_overflow": false, "_charCount": 380, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 61, "_maxCharsPerItem": 122 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 42 } ], "direction": "col" }, { "span": 6, "header": "FDA Approval Trends by Therapeutic Area", "content": { "type": "chart", "series": [ { "data": [ 19, 21, 18, 23, 20, 18 ], "name": "Oncology" }, { "data": [ 10, 14, 12, 15, 13, 12 ], "name": "Rare Disease" }, { "data": [ 24, 15, 7, 17, 17, 15 ], "name": "Other" } ], "stacked": true, "chartType": "bar", "categories": [ "2020", "2021", "2022", "2023", "2024", "2025E" ], "gridBottom": 45, "showBarValues": false }, "_headerMaxChars": 44 } ], "direction": "row" }, "type": "grid", "title": "FDA Turbulence: Risk and Opportunity", "footer": "Source: Evaluate Pharma 2026 Preview; STAT News; Nature Medicine", "sectionLabel": "FDA TURBULENCE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 36, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "7." } ], "text": "7.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "WHERE CAPITAL IS FLOWING", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 24, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772024967315-b15d1ffac756.png", "type": "image", "prompt": "professional subtle luxury small molecule pattern with color #012179", "source": "ai" }, "background": "#2F5496" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 6, "children": [ { "span": 5, "header": "VC Funding by Modality", "content": { "type": "chart", "items": [ { "name": "Oncology Platform", "value": 28 }, { "name": "Metabolic/GLP-1", "value": 22 }, { "name": "Cell/Gene Therapy", "value": 18 }, { "name": "CNS", "value": 12 }, { "name": "Rare Disease", "value": 10 }, { "name": "Other", "value": 10 } ], "centerY": "45%", "doughnut": true, "chartType": "pie", "showLegend": true, "outerRadius": "70%", "labelPosition": "inside" }, "_headerMaxChars": 35 }, { "span": 4, "header": "Average Valuation Premium", "content": { "type": "chart", "series": [ { "data": [ 3.2, 1.8, 1.2, 0.7, 0.4 ], "name": "EV/Pipeline Asset Value Premium (x)" } ], "barColor": "#4472C4", "gridLeft": 120, "chartType": "bar", "categories": [ "Platform Biotech", "Single-Asset Ph3", "Single-Asset Ph2", "Single-Asset Ph1", "Discovery Stage" ], "gridBottom": 20, "horizontal": true, "valueSuffix": "x", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 28 }, { "span": 3, "header": "Top VC Funds (2025)", "content": { "data": { "rows": [ [ "ARCH Venture", "Platforms", "12" ], [ "Flagship", "Novel bio", "8" ], [ "Third Rock", "Oncology", "9" ], [ "OrbiMed", "Broad", "22" ], [ "RA Capital", "Clinical", "18" ] ], "headers": [ "Fund", "Focus", "2025 Deals" ], "fontSize": 900, "colWidths": [ 5, 4, 3 ], "rowHeight": 0.2, "_cellMaxChars": [ 13, 10, 6 ], "_headersMaxChars": [ 26, 20, 12 ] }, "type": "table", "_maxRows": 10, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 20 } ], "direction": "row" }, { "span": 6, "header": "Key Themes Attracting Capital in 2025\u20132026", "content": { "type": "bulletList", "items": [ "AI Drug Discovery: Recursion, Exscientia raising at premium \u2014 science must still work", "Radiopharmaceuticals: Lilly/Aktis and AZ/RayzeBio signal a new arms race in targeted therapy", "Oncology: KRAS, PRMT5, CDK4 with biomarker-selected patient populations", "Protein Degraders: BMS and Pfizer betting on PROTAC/molecular glues" ], "fontSize": 1000, "_maxChars": 846, "_maxLines": 6, "_overflow": false, "_charCount": 315, "_lineCount": 4, "lineSpacing": 2, "_charsPerLine": 141, "_maxCharsPerItem": 141 }, "_headerMaxChars": 92 } ], "direction": "col" }, "type": "grid", "title": "Platform vs. Asset: Capital Bifurcates", "footer": "Source: PitchBook, SVB Securities, FactSet; Data as of Q4 2025", "sectionLabel": "WHERE CAPITAL IS FLOWING", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 4, "header": "Fund Snapshot", "content": { "type": "statGrid", "items": [ { "label": "AUM (est.)", "value": "$3B+", "sublabel": "ARCH IX closed 2022" }, { "label": "Active portfolio cos.", "value": "~60", "sublabel": "Across all vintages" } ] }, "_headerMaxChars": 28 }, { "span": 8, "header": "Why ARCH Wins: The Deep Science Model", "content": { "type": "bulletList", "items": [ "Lab-to-company: ARCH spins out science from academic labs", "Kadmon, Juno, Alnylam, Relay Tx \u2014 all ARCH-founded", "Holds through IPO; low-turn, high-conviction style", "Key edge: NIH/DoE-adjacent deal flow others can't access" ], "fontSize": 1000, "_maxChars": 623, "_maxLines": 7, "_overflow": false, "_charCount": 213, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 89, "_maxCharsPerItem": 89 }, "_headerMaxChars": 59 } ], "direction": "row" }, { "span": 5, "children": [ { "span": 6, "header": "Selected Exits & Returns (Illustrative $B)", "content": { "type": "chart", "series": [ { "data": [ 9, 32, 1.2, 1.8, 1.9, 0.6 ], "name": "Approx. Peak/Exit Value ($B)" } ], "barColor": "#4472C4", "gridLeft": 80, "chartType": "bar", "categories": [ "Juno (JUNO)", "Alnylam (ALNY)", "Relay Tx", "Lyell Imm.", "Armo Bio", "Nuvation" ], "gridBottom": 60, "valueSuffix": "B", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Key Active Holdings (2025)", "content": { "data": { "rows": [ [ "Neumora Tx", "CNS platform", "Phase 2", "Depression/schiz" ], [ "Dewpoint Tx", "Condensate bio", "Phase 1", "Undruggable targets" ], [ "Boundless Bio", "ecDNA", "Phase 2", "Novel resistance" ], [ "Rapport Tx", "GABA mod.", "Phase 2", "CNS selectivity" ], [ "iTeos Tx", "Immuno-oncol.", "Phase 2", "TIGIT/A2AR axis" ] ], "headers": [ "Company", "Modality", "Stage", "Thesis" ], "fontSize": 900, "colWidths": [ 3, 3, 2, 5 ], "rowHeight": 0.24, "_cellMaxChars": [ 15, 15, 9, 28 ], "_headersMaxChars": [ 30, 30, 18, 56 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Investment Strategy & LP Positioning", "content": { "type": "statGrid", "items": [ { "label": "Typical hold", "value": "7\u201312 yrs", "sublabel": "Patient capital model" }, { "label": "Sweet spot", "value": "TRL 3\u20135", "sublabel": "Pre-IND to Phase 1" }, { "label": "Geography", "value": "US-only", "sublabel": "Boston/SF/Chicago" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "ARCH is the canonical platform-first VC", "Alnylam alone = decades of IRR", "CNS + condensate bets are contrarian", "LP access remains highly competitive" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 141, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "ARCH Venture: Deep Science Platform", "footer": "Source: ARCH Venture Partners, PitchBook, Crunchbase, public filings. Data as of Q4 2025.", "sectionLabel": "WHERE CAPITAL IS FLOWING", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 35, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 4, "header": "Fund Snapshot", "content": { "type": "statGrid", "items": [ { "label": "AUM (est.)", "value": "$4.5B+", "sublabel": "Flagship VIII 2023" }, { "label": "Companies created", "value": "100+", "sublabel": "Since 2000" } ] }, "_headerMaxChars": 28 }, { "span": 8, "header": "Why Flagship Is Structurally Different", "content": { "type": "bulletList", "items": [ "Explorations: internal R&D labs generate 200+ ideas/yr", "Keeps 30\u201350% equity; operates as long-term co-founder", "Moderna mRNA platform = proof the model scales globally", "Three new S-corps in stealth per quarter on average" ], "fontSize": 1000, "_maxChars": 623, "_maxLines": 7, "_overflow": false, "_charCount": 213, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 89, "_maxCharsPerItem": 89 }, "_headerMaxChars": 59 } ], "direction": "row" }, { "span": 5, "children": [ { "span": 6, "header": "Flagship Portfolio Value Over Time ($B est.)", "content": { "type": "chart", "series": [ { "data": [ 4, 7, 28, 95, 38, 22, 18, 25 ], "name": "Total Portfolio Value ($B)" } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "2018", "2019", "2020", "2021", "2022", "2023", "2024", "2025E" ], "gridBottom": 60, "showLineValues": false }, "_headerMaxChars": 44 }, { "span": 6, "header": "Key Active Holdings (2025)", "content": { "data": { "rows": [ [ "Moderna", "mRNA platform", "Coml.", "COVID + RSV appr." ], [ "Larimar Tx", "FA (frataxin)", "Phase 3", "Rare neuro" ], [ "Generate Bio", "AI protein design", "Discov.", "ML-native" ], [ "Quotient Bio", "Microfluidics", "Phase 1", "Oral biologics" ], [ "Tessera Tx", "Gene writing", "Discov.", "Beyond CRISPR" ] ], "headers": [ "Company", "Focus", "Stage", "Notable" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 4 ], "rowHeight": 0.24, "_cellMaxChars": [ 20, 20, 8, 20 ], "_headersMaxChars": [ 40, 40, 16, 40 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Investment Model & LP Profile", "content": { "type": "statGrid", "items": [ { "label": "Concept to IPO", "value": "5\u20138 yrs", "sublabel": "Internal creation timeline" }, { "label": "Exploration budget", "value": "$50M/yr", "sublabel": "Unfunded R&D arm" }, { "label": "Co-investors", "value": "Rare", "sublabel": "Leads solo most rounds" }, { "label": "Novo Holdings", "value": "Key LP", "sublabel": "Strategic alignment" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Moderna validates the full thesis", "Post-peak; portfolio reset in progress", "Generate Bio = most watched asset now", "Model is hard to replicate at scale" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 143, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Flagship Pioneering: Company Creator", "footer": "Source: Flagship Pioneering, PitchBook, SEC filings, Evaluate Pharma. Data as of Q4 2025.", "sectionLabel": "WHERE CAPITAL IS FLOWING", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 36, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 4, "header": "Fund Snapshot", "content": { "type": "statGrid", "items": [ { "label": "AUM", "value": "$18B+", "sublabel": "VC + public + royalty" }, { "label": "Active investments", "value": "200+", "sublabel": "Across stages/geographies" } ] }, "_headerMaxChars": 28 }, { "span": 8, "header": "Why OrbiMed Spans the Full Stack", "content": { "type": "bulletList", "items": [ "Only fund with VC, crossover, public, and royalty vehicles", "CN presence (OrbiMed Asia) captures China out-licensing deals", "Clinical-stage sweet spot: Ph2 data + biomarker story", "22 deals in 2025 = highest volume of any dedicated HC fund" ], "fontSize": 1000, "_maxChars": 623, "_maxLines": 7, "_overflow": false, "_charCount": 230, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 89, "_maxCharsPerItem": 89 }, "_headerMaxChars": 59 } ], "direction": "row" }, { "span": 5, "children": [ { "span": 6, "header": "2025 Portfolio Mix by Stage (%)", "content": { "type": "chart", "items": [ { "name": "Phase 2/3", "value": 35 }, { "name": "Phase 1", "value": 25 }, { "name": "Public crossover", "value": 20 }, { "name": "Discovery/Pre-IND", "value": 12 }, { "name": "Royalty/structured", "value": 8 } ], "centerY": "45%", "doughnut": true, "chartType": "pie", "gridBottom": 60, "showLegend": true, "outerRadius": "70%", "labelPosition": "inside" }, "_headerMaxChars": 44 }, { "span": 6, "header": "Key Holdings Across Vehicles (2025)", "content": { "data": { "rows": [ [ "Black Diamond Tx", "EGFR allosteric", "Phase 2", "VC" ], [ "Protagonist Tx", "Peptide mimetics", "Phase 3", "Public" ], [ "Elevation Oncol.", "SHP2 inhibitor", "Phase 2", "VC" ], [ "Invacare (royalty)", "Medical devices", "Revenue", "Royalty" ], [ "Gracell Bio", "CAR-T platform", "Ph2 (CN)", "Asia VC" ] ], "headers": [ "Company", "Modality", "Stage", "Vehicle" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.24, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Cross-Vehicle Strategy & Edge", "content": { "type": "statGrid", "items": [ { "label": "VC fund size", "value": "$3B", "sublabel": "OrbiMed Private V" }, { "label": "Public book", "value": "$8B", "sublabel": "Long/short HC equities" }, { "label": "OrbiMed Asia", "value": "$2B", "sublabel": "CN/APAC VC vehicle" }, { "label": "Royalty vehicle", "value": "$1B+", "sublabel": "Non-dilutive financing" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Broadest platform of any HC-only fund", "Asia vehicle = early CN out-license edge", "Public book creates crossover arbitrage", "Volume player; quality varies by vehicle" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 156, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "OrbiMed: Largest Dedicated Healthcare VC", "footer": "Source: OrbiMed Advisors, PitchBook, SEC 13F filings, Evaluate Pharma. Data as of Q4 2025.", "sectionLabel": "WHERE CAPITAL IS FLOWING", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 40, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "8." } ], "text": "8.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "M&A LANDSCAPE", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 13, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772025012029-4b8aba6670d2.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#4472C4" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Select Significant Transactions (2024\u20132025)", "content": { "data": { "rows": [ [ "Pfizer", "Seagen", "$43B", "ADC platform" ], [ "AbbVie", "Cerevel", "$8.7B", "CNS/emraclidine" ], [ "AbbVie", "ImmunoGen", "$10.1B", "ADC/ELAHERE" ], [ "AstraZeneca", "Gracell Bio", "$1.2B", "CAR-T platform" ], [ "Eli Lilly", "Aktis Oncology", "$1.4B", "Radiopharm" ], [ "BMS", "RayzeBio", "$4.1B", "Ac-225 therapy" ] ], "headers": [ "Acquirer", "Target", "Value", "Rationale" ], "fontSize": 850, "colWidths": [ 3, 3, 2, 4 ], "rowHeight": 0.2, "_cellMaxChars": [ 21, 21, 13, 30 ], "_headersMaxChars": [ 42, 42, 26, 60 ] }, "type": "table", "_maxRows": 10, "_overflow": false, "_rowCount": 6 }, "_headerMaxChars": 52 }, { "span": 6, "header": "M&A Volume & Premium Trends", "content": { "bars": [ { "data": [ 80, 120, 65, 95, 145, 160 ], "name": "Deal Volume ($B)" } ], "type": "chart", "lines": [ { "data": [ 55, 68, 52, 61, 72, 78 ], "name": "Avg. Premium (%)" } ], "dualAxis": true, "chartType": "combo", "categories": [ "2020", "2021", "2022", "2023", "2024", "2025E" ], "gridBottom": 45 }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "What the Market Is Getting Wrong", "content": { "type": "bulletList", "items": [ "M&A premiums are justified \u2014 scarcity of late-stage de-risked assets is real", "ADC hype is correct: Pfizer/Seagen commercial execution proves platform thesis", "Radiopharmaceuticals: actinium-225 supply is a durable strategic moat", "Consensus too bearish on allogeneic CAR-T \u2014 contrarian bullish" ], "fontSize": 1000, "_maxChars": 588, "_maxLines": 12, "_overflow": false, "_charCount": 285, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 49, "_maxCharsPerItem": 147 }, "padding": 0.1, "background": "#EBF3FF", "_headerMaxChars": 34 }, { "span": 6, "header": "Most Likely Next Wave of Targets", "content": { "type": "bulletList", "items": [ "Protagonist Therapeutics: Phase 3 GI programs, IND-approved in multiple anemias", "Karuna Therapeutics: acquired \u2014 but precedent = neuropsych valuations supportable", "Merus N.V.: multi-specific antibody platform, undervalued", "Relay Therapeutics: precision oncology, FGFR2 franchise", "Instil Bio / Iovance: TIL cell therapy for solid tumors" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 327, "_lineCount": 10, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 104 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "M&A: Buyers, Targets & Mispriced Assets", "footer": "Source: Evaluate Pharma; FactSet; Company filings; Evaluate 2026 Preview Jan 2026", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 39, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 3, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$2.8B", "sublabel": "NASDAQ: PTGX" }, { "label": "Cash runway", "value": ">2 yrs", "sublabel": "$420M cash Q3 2025" }, { "label": "Lead catalyst", "value": "H1 2025", "sublabel": "Rusfertide Ph3 PV data" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why Protagonist Is a Prime Target", "content": { "type": "bulletList", "items": [ "Rusfertide: first-in-class hepcidin mimetic, Ph3 PV data H1 2025", "Oral IL-23 platform: peptide mimetics dodge biologic IP moats", "JNJ already validated category via Tremfya/guselkumab franchise", "OrbiMed, Janus among largest holders \u2014 activist-friendly cap table" ], "fontSize": 1000, "_maxChars": 320, "_maxLines": 5, "_overflow": false, "_charCount": 254, "_lineCount": 5, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 6, "header": "Revenue Potential by Asset ($M peak est.)", "content": { "type": "chart", "series": [ { "data": [ 900, 600, 1200, 500 ], "name": "Peak Sales Est. ($M)" } ], "barColor": "#4472C4", "gridLeft": 110, "chartType": "bar", "categories": [ "Rusfertide PV", "Rusfertide ET/MF", "PTG-100 IBD", "PN-943 UC" ], "gridBottom": 60, "horizontal": true, "valueSuffix": "M", "showBarValues": true, "valueDecimals": 0 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Comparable M&A Transactions", "content": { "data": { "rows": [ [ "JNJ", "Aragon Pharma", "$1.0B", "Peptide" ], [ "Pfizer", "Arena Pharma", "$6.7B", "Oral GI" ], [ "AbbVie", "Allergan", "$63B", "Platform" ], [ "Roche", "Inflazome", "$0.4B", "Oral IL" ], [ "Sanofi", "Kadmon", "$1.9B", "TGF-beta" ] ], "headers": [ "Acquirer", "Target", "Value", "Modality" ], "fontSize": 900, "colWidths": [ 3, 4, 2, 4 ], "rowHeight": 0.16, "_cellMaxChars": [ 15, 22, 9, 22 ], "_headersMaxChars": [ 30, 44, 18, 44 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "M&A Valuation Framework", "content": { "type": "statGrid", "items": [ { "label": "rNPV (base)", "value": "$3.8B", "sublabel": "15% cost of capital" }, { "label": "Takeout premium", "value": "40\u201360%", "sublabel": "vs. 30d VWAP" }, { "label": "Implied EV", "value": "$3.9\u20135.0B", "sublabel": "Plausible range" }, { "label": "Best fit buyer", "value": "JNJ AbbVie", "sublabel": "IL-23 / GI franchise" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Ph3 readout = binary event in H1 25", "Positive data = immediate takeout target", "Oral IL-23 alone worth $2B+ to JNJ", "Risk: Ph3 miss = significant downside" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 146, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Protagonist Tx: Hepcidin & Oral IL-23", "footer": "Source: Protagonist Therapeutics SEC filings, ClinicalTrials.gov, Evaluate Pharma. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 37, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt-Style \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 1, 0, 1, 0 ], "name": "_offset", "color": "transparent" }, { "data": [ 2, 3, 3, 0, 3 ], "name": "Phase 3", "color": "#4472C4" }, { "data": [ 1, 1, 0, 0, 0 ], "name": "NDA/Filing", "color": "#ED7D31" }, { "data": [ 1, 0, 0, 0, 0 ], "name": "Approval", "color": "#FF0000" }, { "data": [ 0, 0, 3, 4, 2 ], "name": "Phase 2", "color": "#A9D18E" } ], "stacked": true, "gridLeft": 130, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "Rusfertide (PTG-300) - PV", "Rusfertide - ET/MF", "PTG-100 (oral IL-23)", "PTG-200 (oral IL-23 IBD)", "PN-943 (oral GI-restrict.)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false, "xAxisCategories": [ "H1'25", "H2'25", "H1'26", "H2'26", "H1'27", "H2'27", "H1'28", "H2'28" ] }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Data Readouts & Catalysts", "content": { "data": { "rows": [ [ "Rusfertide", "Ph3 ACTIVATE+ data", "H1 2025", "Binary/high" ], [ "Rusfertide", "NDA submission", "H2 2025", "High" ], [ "PN-943", "Ph2b UC readout", "H2 2025", "Medium" ], [ "PTG-100", "Ph2 Crohn's data", "H1 2026", "Medium" ], [ "Rusfertide ET", "Ph3 enroll complete", "H2 2025", "Low-med" ] ], "headers": [ "Asset", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 4 ], "rowHeight": 0.17, "_cellMaxChars": [ 20, 20, 8, 20 ], "_headersMaxChars": [ 40, 40, 16, 40 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Competitive Landscape", "content": { "data": { "rows": [ [ "Incyte", "Ruxolitinib", "JAK1/2", "Approved" ], [ "AbbVie", "Upadacitinib", "JAK1", "Approved" ], [ "Celldex", "Barzolvolimab", "KIT", "Phase 3" ], [ "Disc Med.", "Luspatercept", "TGF-b", "Approved" ], [ "Blueprint", "Avapritinib", "PDGFRA", "Approved" ] ], "headers": [ "Competitor", "Asset", "Target", "Stage" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 2 ], "rowHeight": 0.17, "_cellMaxChars": [ 24, 17, 17, 10 ], "_headersMaxChars": [ 48, 34, 34, 20 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Protagonist: Full Pipeline Timeline", "footer": "Source: Protagonist Therapeutics SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 35, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$3.1B", "sublabel": "NASDAQ: MRUS" }, { "label": "Cash", "value": "$680M", "sublabel": "Runway >3 years" }, { "label": "Zenoc. FDA PDUFA", "value": "Aug 2025", "sublabel": "NRG1+ NSCLC/PDAC" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why Merus Commands a Platform Premium", "content": { "type": "bulletList", "items": [ "Biclonics platform: proprietary full-length bispecific antibodies", "Zenocutuzumab: first-ever approved Rx for NRG1-fusion cancers", "Lilly partnership ($1.5B deal 2024) = external platform validation", "LGR5/EGFR (MCLA-158): Sanofi interested; stem-cell targeting moat" ], "fontSize": 1000, "_maxChars": 448, "_maxLines": 7, "_overflow": false, "_charCount": 257, "_lineCount": 7, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 5, "children": [ { "span": 6, "header": "Biclonics Platform Value Drivers ($B)", "content": { "type": "chart", "series": [ { "data": [ 1.4, 0.6, 0.9, 0.4, 0.8 ], "name": "rNPV Est. ($B)" } ], "barColor": "#4472C4", "gridLeft": 130, "chartType": "bar", "categories": [ "Zenocutuzumab", "MCLA-129", "MCLA-158", "MCLA-145", "Platf. royalties" ], "gridBottom": 60, "horizontal": true, "valueSuffix": "B", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Bispecific Antibody M&A Comps", "content": { "data": { "rows": [ [ "Roche", "Genentech", "$46.8B", "Platform" ], [ "AZ", "Gracell Bio", "$1.2B", "CAR-T bispfc" ], [ "JNJ", "Ambrx", "$2.0B", "Bispfc ADC" ], [ "BMS", "Turning Point", "$4.1B", "Bispfc KIT" ], [ "Lilly", "Merus (part.)", "$1.5B", "Biclonics deal" ] ], "headers": [ "Acquirer", "Target", "Value", "Rationale" ], "fontSize": 900, "colWidths": [ 3, 4, 2, 4 ], "rowHeight": 0.16, "_cellMaxChars": [ 15, 22, 9, 22 ], "_headersMaxChars": [ 30, 44, 18, 44 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "M&A Valuation Framework", "content": { "type": "statGrid", "items": [ { "label": "rNPV (base)", "value": "$4.1B", "sublabel": "12% cost of capital" }, { "label": "Takeout premium", "value": "40\u201370%", "sublabel": "Platform scarcity" }, { "label": "Implied EV", "value": "$4.3\u20135.3B", "sublabel": "Plausible range" }, { "label": "Best fit buyer", "value": "Roche/AZ/BMS", "sublabel": "Bispecific pipeline gaps" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Zenocutuzumab approval = derisked base", "Lilly deal proves platform is real", "MCLA-158 is the hidden gem asset", "Roche is natural buyer; fits HER2 gap" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 141, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Merus N.V.: Multi-Specific Ab Platform", "footer": "Source: Merus N.V. SEC filings, ClinicalTrials.gov, Evaluate Pharma. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt-Style \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 0, 0, 1, 2 ], "name": "_offset", "color": "transparent" }, { "data": [ 1, 3, 3, 0, 0 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 1, 0, 0, 0, 0 ], "name": "NDA/Filing", "color": "#ED7D31" }, { "data": [ 1, 0, 0, 0, 0 ], "name": "Approval", "color": "#FF0000" }, { "data": [ 0, 3, 2, 4, 4 ], "name": "Phase 1/2", "color": "#A9D18E" } ], "stacked": true, "gridLeft": 130, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "Zenocutuzumab (NRG1+)", "MCLA-129 (EGFR/c-Met)", "MCLA-158 (LGR5/EGFR)", "MCLA-145 (PD-L1/CD137)", "MCLA-294 (ADAM10/Notch)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false, "xAxisCategories": [ "H1'25", "H2'25", "H1'26", "H2'26", "H1'27", "H2'27", "H1'28", "H2'28" ] }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "Zenocutuzumab", "FDA PDUFA date", "Aug 2025", "High" ], [ "Zenocutuzumab", "PDAC launch data", "H2 2025", "High" ], [ "MCLA-129", "Ph1/2 dose-escalation", "H1 2026", "Medium" ], [ "MCLA-158", "Ph1/2 expansion data", "H2 2026", "Medium" ], [ "MCLA-145", "Ph1 safety readout", "H1 2026", "Low-med" ] ], "headers": [ "Asset", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "NRG1-Fusion Competitive Landscape", "content": { "data": { "rows": [ [ "Merus", "Zenocutuzumab", "HER2/HER3", "NDA filed" ], [ "Relay Tx", "RLY-2608", "PI3K", "Phase 2" ], [ "Daiichi/AZ", "Patritumab", "HER3 ADC", "Phase 3" ], [ "Lilly (MCLA-128)", "Zenocutuzumab", "NRG1", "Phase 2" ], [ "Elevation", "EP-100", "LHRH/EGFR", "Phase 2" ] ], "headers": [ "Company", "Drug", "Target", "Status" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 15, 15, 15 ], "_headersMaxChars": [ 44, 30, 30, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Merus: Full Pipeline Timeline", "footer": "Source: Merus N.V. SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 29, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$1.2B", "sublabel": "NASDAQ: RLAY" }, { "label": "Cash", "value": "$475M", "sublabel": ">2 yr runway" }, { "label": "Lead catalyst", "value": "H1 2025", "sublabel": "RLY-4008 NDA filing" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why Relay Is an Undervalued Platform", "content": { "type": "bulletList", "items": [ "Conformational dynamics: targets mutant-selective binding pockets", "RLY-4008: only allosteric FGFR2i; NDA filing H1 2025 for PDAC", "RLY-2608: PI3Ka mutant-selective; avoids toxicity of pan-PI3Ki", "ARCH-backed; founders = Stanford comput. biology / ML credibility" ], "fontSize": 1000, "_maxChars": 448, "_maxLines": 7, "_overflow": false, "_charCount": 253, "_lineCount": 6, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 5, "children": [ { "span": 6, "header": "Asset rNPV vs. Market Cap Disconnect ($B)", "content": { "type": "chart", "series": [ { "data": [ 1.2, 1.1, 0.9, 0.8 ], "name": "Value ($B)" } ], "barColor": "#4472C4", "gridLeft": 120, "chartType": "bar", "categories": [ "Current Mkt Cap", "RLY-4008 rNPV", "RLY-2608 rNPV", "Platform value" ], "gridBottom": 60, "valueSuffix": "B", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Precision Oncology M&A Comps", "content": { "data": { "rows": [ [ "BMS", "Turning Point", "$4.1B", "RET/MET prec." ], [ "Pfizer", "Array Bio", "$11.4B", "BRAF/MEK" ], [ "Lilly", "Prevail Tx", "$1.0B", "CNS precision" ], [ "JNJ", "Ambrx Bio", "$2.0B", "ADC platform" ], [ "Roche", "Spark Tx", "$4.3B", "Gene therapy" ] ], "headers": [ "Acquirer", "Target", "Value", "Rationale" ], "fontSize": 900, "colWidths": [ 3, 4, 2, 4 ], "rowHeight": 0.16, "_cellMaxChars": [ 15, 22, 9, 22 ], "_headersMaxChars": [ 30, 44, 18, 44 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "M&A Valuation Framework", "content": { "type": "statGrid", "items": [ { "label": "rNPV (base)", "value": "$2.8B", "sublabel": "15% cost of capital" }, { "label": "Takeout premium", "value": "50\u201380%", "sublabel": "Depressed stock" }, { "label": "Implied EV", "value": "$1.8\u20132.2B", "sublabel": "Plausible near-term" }, { "label": "Best fit buyer", "value": "AZ / Roche", "sublabel": "FGFR/PI3K franchise" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Most mispriced asset in our coverage", "NDA filing = immediate re-rating event", "RLY-2608 differentiates from IQVIA data", "AZ is natural buyer; FGFR2 fits oncol." ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 151, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Relay Therapeutics: Precision Oncology", "footer": "Source: Relay Therapeutics SEC filings, ClinicalTrials.gov, Evaluate Pharma. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt-Style \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 0, 1, 0, 0 ], "name": "_offset", "color": "transparent" }, { "data": [ 2, 3, 0, 3, 0 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 1, 0, 0, 0, 0 ], "name": "NDA/Filing", "color": "#ED7D31" }, { "data": [ 1, 0, 0, 0, 0 ], "name": "Approval", "color": "#FF0000" }, { "data": [ 0, 2, 4, 3, 4 ], "name": "Phase 1/2", "color": "#A9D18E" }, { "data": [ 0, 3, 0, 0, 0 ], "name": "Phase 3", "color": "#7030A0" }, { "data": [ 0, 0, 0, 0, 2 ], "name": "Preclinical", "color": "#D9D9D9" } ], "stacked": true, "gridLeft": 130, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "RLY-4008 (FGFR2 allosteric)", "RLY-2608 (PI3Ka allosteric)", "RLY-5836 (PI3Kd)", "RLY-1971 (SHP2 inh.)", "Preclinical (conformat.)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false, "xAxisCategories": [ "H1'25", "H2'25", "H1'26", "H2'26", "H1'27", "H2'27", "H1'28", "H2'28" ] }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "RLY-4008", "NDA filing FGFR2+ PDAC", "H1 2025", "High" ], [ "RLY-4008", "FDA PDUFA", "H2 2025", "High" ], [ "RLY-2608", "Ph2 ORR readout", "H2 2025", "High" ], [ "RLY-2608", "Ph3 start (BC)", "H1 2026", "Medium" ], [ "RLY-5836", "Ph1 safety data", "H1 2026", "Low-med" ] ], "headers": [ "Asset", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "FGFR2 & PI3Ka Competitive Landscape", "content": { "data": { "rows": [ [ "Incyte", "Pemigatinib", "FGFR1-3", "Approved" ], [ "JNJ", "Erdafitinib", "FGFR1-4", "Approved" ], [ "AZ", "Capivasertib", "AKT1", "Approved" ], [ "Novartis", "Alpelisib", "PI3Ka", "Approved" ], [ "Relay", "RLY-2608", "PI3Ka mut", "Phase 2" ] ], "headers": [ "Company", "Drug", "Target", "Status" ], "fontSize": 900, "colWidths": [ 3, 4, 3, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 15, 22, 15, 15 ], "_headersMaxChars": [ 30, 44, 30, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Relay Therapeutics: Full Pipeline Timeline", "footer": "Source: Relay Therapeutics SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": true, "_footerMaxChars": 184, "_titleCharCount": 42, "_titleLineCount": 2, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 4, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$3.4B", "sublabel": "NASDAQ: IOVA" }, { "label": "Amtagvi launch", "value": "2024", "sublabel": "1st TIL therapy approved" }, { "label": "2025E revenue", "value": "$300M+", "sublabel": "Ramp quarter-on-quarter" } ] }, "_headerMaxChars": 37 }, { "span": 8, "header": "Why Iovance Is an M&A Candidate Now", "content": { "type": "bulletList", "items": [ "Amtagvi: first-in-history approved TIL cell therapy (mela., Feb 2024)", "Expanding to NSCLC and H&N SCC \u2014 market >10x vs. melanoma alone", "Manufacturing scale-up at Philadelphia site de-risks supply chain", "BMS / Pfizer both lack solid-tumor cell therapy \u2014 obvious strategic fit" ], "fontSize": 1000, "_maxChars": 525, "_maxLines": 7, "_overflow": false, "_charCount": 268, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 75, "_maxCharsPerItem": 75 }, "_headerMaxChars": 50 } ], "direction": "row" }, { "span": 5, "children": [ { "span": 6, "header": "Amtagvi Revenue Ramp vs. Yescarta ($M)", "content": { "type": "chart", "series": [ { "data": [ 12, 35, 62, 90, 120, 155, 190, 230 ], "name": "Amtagvi ($M)" }, { "data": [ 18, 42, 71, 105, 145, 185, 225, 265 ], "name": "Yescarta Y1 comp." } ], "smooth": true, "chartType": "line", "lineWidth": 2, "categories": [ "Q1'24", "Q2'24", "Q3'24", "Q4'24", "Q1'25E", "Q2'25E", "Q3'25E", "Q4'25E" ], "gridBottom": 60 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Cell Therapy M&A Comps", "content": { "data": { "rows": [ [ "BMS", "Celgene", "$74B", "CAR-T platform" ], [ "Gilead", "Kite Pharma", "$11.9B", "CD19 CAR-T" ], [ "JNJ", "Legend Bio (part)", "$5.0B", "BCMA CAR-T" ], [ "AZ", "Gracell Bio", "$1.2B", "CAR-T CN" ], [ "Novartis", "Tisagenlecleucel", "In-house", "CAR-T (Kymriah)" ] ], "headers": [ "Acquirer", "Target", "Value", "Modality" ], "fontSize": 900, "colWidths": [ 3, 4, 2, 4 ], "rowHeight": 0.16, "_cellMaxChars": [ 15, 22, 9, 22 ], "_headersMaxChars": [ 30, 44, 18, 44 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "M&A Valuation Framework", "content": { "type": "statGrid", "items": [ { "label": "rNPV (base)", "value": "$5.2B", "sublabel": "12% cost of capital" }, { "label": "Takeout premium", "value": "30\u201350%", "sublabel": "Revenue ramp de-risks" }, { "label": "Implied EV", "value": "$4.4\u20135.1B", "sublabel": "Plausible range" }, { "label": "Best fit buyer", "value": "BMS / Pfizer", "sublabel": "Solid tumor cell Rx gap" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Only commercial TIL asset globally", "NSCLC label = 10x melanoma addressable", "Manufacturing IP is the real moat", "BMS is the most natural acquirer here" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 142, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Iovance: TIL Cell Therapy", "footer": "Source: Iovance Biotherapeutics SEC filings, ClinicalTrials.gov, Evaluate Pharma. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 25, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 7, "header": "Development Timeline (Gantt-Style \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 0, 0, 1, 0 ], "name": "_offset", "color": "transparent" }, { "data": [ 8, 0, 0, 0, 0 ], "name": "Commercial", "color": "#FF0000" }, { "data": [ 0, 3, 2, 3, 0 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 0, 4, 4, 0, 0 ], "name": "Phase 3", "color": "#7030A0" }, { "data": [ 0, 0, 0, 3, 5 ], "name": "Phase 1/2", "color": "#A9D18E" }, { "data": [ 0, 0, 0, 0, 1 ], "name": "Preclinical", "color": "#D9D9D9" } ], "stacked": true, "gridLeft": 130, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "Lifileucel (Amtagvi) - mela.", "Lifileucel - NSCLC", "Lifileucel - H&N SCC", "IOV-3001 (IL-2 TIL combo)", "Next-gen TIL (autolog.)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false, "xAxisCategories": [ "H1'25", "H2'25", "H1'26", "H2'26", "H1'27", "H2'27", "H1'28", "H2'28" ] }, "_headerMaxChars": 92 }, { "span": 5, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "Amtagvi", "Q1 2025 revenue print", "Apr 2025", "High" ], [ "Lifileucel NSCLC", "Ph2 NSCLC ORR data", "H2 2025", "V.High" ], [ "Lifileucel H&N", "Ph2 H&N data", "H1 2026", "High" ], [ "IOV-3001", "Ph1/2 combo data", "H2 2026", "Medium" ], [ "Amtagvi", "EU approval decision", "H1 2026", "Medium" ] ], "headers": [ "Asset", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "TIL / Solid Tumor Cell Tx Landscape", "content": { "data": { "rows": [ [ "Iovance", "Amtagvi", "TIL (pan)", "Approved" ], [ "Instil Bio", "ITIL-168", "TIL", "Phase 2" ], [ "Achilles Tx", "NTRT", "Neoantigen TIL", "Phase 1/2" ], [ "BioNTech", "BNT221", "TIL", "Phase 1/2" ], [ "Adaptimmune", "Afami-cel", "MAGE-A4 TCR", "Approved" ] ], "headers": [ "Company", "Asset", "Target", "Status" ], "fontSize": 900, "colWidths": [ 3, 4, 3, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 15, 22, 15, 15 ], "_headersMaxChars": [ 30, 44, 30, 30 ] }, "type": "table", "_maxRows": 9, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Iovance: Full Pipeline Timeline", "footer": "Source: Iovance Biotherapeutics SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "M&A LANDSCAPE", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 31, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "runs": [ { "text": "9." } ], "text": "9.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 2, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "THEMES BEYOND GLP-1", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 19, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772024988623-10ffeee1bfaf.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#2F5496" } ], "direction": "row" }, "type": "grid" }, { "type": "grid", "title": "Themes Beyond the GLP-1 Frenzy", "footer": "Source: Company filings, ClinicalTrials.gov, PitchBook, Evaluate Pharma", "$template": "keyTrends", "sectionLabel": "THEMES BEYOND GLP-1", "$templateData": { "title": "Three Underappreciated Themes Beyond the GLP-1 Frenzy", "columns": [ { "text": { "type": "bulletList", "items": [ "Targeted alpha therapy (TAT) using actinium-225 and bismuth-213 delivering lethal radiation within millimeters of tumor", "Novartis Lutathera/Pluvicto proving commercial model; Bristol-Myers RayzeBio deal validates category", "Supply chain constraint = durable competitive moat; not easily replicated by Big Pharma", "Pipeline expanding beyond PSMA prostate cancer to GRPR breast, SSTR2 NETs, FAPi solid tumors", "Under-the-radar companies: Fusion Pharma (AZ acquired), RadioMedix, Ratio Therapeutics" ], "lineSpacing": "single" }, "header": "Radiopharmaceuticals", "visual": { "type": "chart", "series": [ { "data": [ 2.1, 3.4, 5.8, 8.2, 11.5 ], "name": "RxPharma Market ($B)" } ], "barColor": "#4472C4", "chartType": "bar", "categories": [ "2022", "2023", "2024", "2025E", "2026E" ], "valuePrefix": "$", "valueSuffix": "B", "showBarValues": true } }, { "text": { "type": "bulletList", "items": [ "Molecular glues can hit 'undruggable' targets that small molecules and antibodies cannot address", "C3 Therapeutics, Kymera Therapeutics, Arvinas leading the field with Phase 2+ data", "Bristol-Myers Squibb and Pfizer both acquired degrader platforms 2023\u201324", "GSPT1, IKZF1/3, AR-v7 are validated glue targets with near-term clinical readouts", "Oral bioavailability and CNS penetration distinguish best-in-class from science projects" ], "lineSpacing": "single" }, "header": "Protein Degraders (PROTAC/Glues)", "visual": { "type": "chart", "items": [ { "name": "PROTAC", "value": 55 }, { "name": "Molecular Glue", "value": 30 }, { "name": "Hydrophobic Tag", "value": 15 } ], "centerY": "45%", "doughnut": true, "chartType": "pie", "showLegend": false, "labelPosition": "inside" } }, { "text": { "type": "bulletList", "items": [ "AbbVie paid $8.7B for Cerevel; Biogen/Eisai Leqembi proving Alzheimer's is a real market", "Muscarinic receptor agonism (M4) is the new SOC for schizophrenia \u2014 emraclidine, xanomeline", "Psychedelic-adjacent: GABA-PAM, NMDA modulators \u2014 COMPASS, Atai Life Sciences navigating regulated path", "Obesity and CNS are converging: GLP-1 receptors in the brain are driving neuroinflammation interest", "Most undervalued: Rare CNS: Huntington's, ALS, Prader-Willi \u2014 small population, high WTP" ], "lineSpacing": "single" }, "header": "CNS Neuropsychiatry", "visual": { "type": "chart", "series": [ { "data": [ 12, 18, 14, 22, 28, 32 ], "name": "CNS M&A Value ($B)" } ], "smooth": true, "chartType": "line", "lineColor": "#4472C4", "lineWidth": 2, "categories": [ "2020", "2021", "2022", "2023", "2024", "2025E" ] } } ], "subtitle": "The market is so focused on obesity/GLP-1 that several equally transformative platform opportunities are being underpriced.", "sectionLabel": "THEMES BEYOND GLP-1" }, "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 30, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 3, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Status", "value": "Private", "sublabel": "Series B 2024" }, { "label": "Raised", "value": "$135M", "sublabel": "ARCH + OrbiMed led" }, { "label": "Lead program", "value": "Ph1", "sublabel": "RAT001 PSMA/Ac-225" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why Ratio Is the Standout in TAT", "content": { "type": "bulletList", "items": [ "Proprietary SARTATE chelator stabilizes Ac-225 vs competitors", "Oak Ridge National Lab supply deal creates structural moat", "PSMA-targeted TAT: 10\u2013100x more potent than Lu-177", "GRPR (breast) + FAPi (pan-solid) expand beyond prostate" ], "fontSize": 1000, "_maxChars": 320, "_maxLines": 5, "_overflow": false, "_charCount": 224, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 6, "header": "TAT Market Size by Indication ($B, 2030E)", "content": { "type": "chart", "series": [ { "data": [ 4.2, 3.1, 2.8, 1.4, 0.9 ], "name": "Addressable Market ($B)" } ], "barColor": "#4472C4", "gridLeft": 120, "chartType": "bar", "categories": [ "PSMA/Prostate", "GRPR/Breast", "FAPi/Solid Tx", "SSTR2/NETs", "Other" ], "gridBottom": 60, "horizontal": true, "valueSuffix": "B", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Radiopharm Competitive Landscape", "content": { "data": { "rows": [ [ "Novartis", "Lu-177", "PSMA/SSTR2", "Commercial" ], [ "BMS/RayzeBio", "Ac-225", "GRPR", "Phase 2" ], [ "AZ/Fusion", "Ac-225", "PSMA", "Phase 2" ], [ "Ratio Tx", "Ac-225", "PSMA/GRPR", "Phase 1" ], [ "RadioMedix", "Ac-225", "PSMA", "Phase 1" ] ], "headers": [ "Company", "Isotope", "Target", "Status" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 3 ], "rowHeight": 0.16, "_cellMaxChars": [ 22, 15, 15, 15 ], "_headersMaxChars": [ 44, 30, 30, 30 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Investment Thesis & Key Metrics", "content": { "type": "statGrid", "items": [ { "label": "Last valuation", "value": "~$600M", "sublabel": "Post Series B 2024" }, { "label": "Key differentiator", "value": "SARTATE", "sublabel": "Proprietary chelator IP" }, { "label": "M&A fit", "value": "AZ / Lilly", "sublabel": "TAT platform gap" }, { "label": "Exit horizon", "value": "2027\u201328", "sublabel": "Ph2 data = takeout" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Chelator IP is the real defensibility", "Ac-225 supply = structural bottleneck", "GRPR breast data = 2026 inflection", "AZ natural buyer post Fusion deal" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 141, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Ratio Therapeutics: Next-Gen TAT", "footer": "Source: Ratio Therapeutics, PitchBook, ClinicalTrials.gov, company press releases. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 32, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 0, 1, 0, 0 ], "name": "_offset", "color": "transparent" }, { "data": [ 2, 3, 3, 0, 0 ], "name": "Phase 1", "color": "#A9D18E" }, { "data": [ 3, 0, 0, 0, 0 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 0, 1, 2, 2, 0 ], "name": "IND-enabling", "color": "#E2EFDA" }, { "data": [ 0, 0, 0, 2, 4 ], "name": "Preclinical", "color": "#D9D9D9" } ], "stacked": true, "gridLeft": 150, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "RAT001 (PSMA, Ac-225)", "RAT002 (GRPR, breast)", "RAT003 (FAPi, solid Tx)", "RAT004 (SSTR2, NETs)", "Chelator platform (novel)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "RAT001", "Ph1 safety + dosing", "H2 2025", "High" ], [ "RAT001", "Ph1 ORR signal", "H1 2026", "V.High" ], [ "RAT002", "IND filing GRPR", "H1 2026", "Medium" ], [ "RAT001", "Ph2 enrollment", "H2 2026", "High" ], [ "RAT003", "IND filing FAPi", "H1 2027", "Medium" ] ], "headers": [ "Program", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Ac-225 Supply Chain Dynamics", "content": { "data": { "rows": [ [ "Oak Ridge NL", "~1 Ci/yr", "Ratio excl.", "US DOE" ], [ "TRIUMF (CA)", "~0.3 Ci/yr", "Multi", "Cyclotron" ], [ "iThemba LABS", "~0.2 Ci/yr", "Open", "SA govt" ], [ "NorthStar Med.", "Scaling", "Novartis", "Reactor" ], [ "Niowave", "Pilot", "TBD", "Linear accel." ] ], "headers": [ "Supplier", "Capacity", "Partner", "Moat" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 15, 15, 15 ], "_headersMaxChars": [ 44, 30, 30, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Ratio Therapeutics: Pipeline Timeline", "footer": "Source: Ratio Therapeutics, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 37, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 3, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$1.6B", "sublabel": "NASDAQ: KYMR" }, { "label": "Cash", "value": "$620M", "sublabel": ">3 yr runway" }, { "label": "Sanofi deal", "value": "$1.45B", "sublabel": "IRAK4 partnership 2021" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why Kymera Leads the Degrader Field", "content": { "type": "bulletList", "items": [ "Pegasus platform: E3-ligase-focused; >80 ligase-target combos", "KT-474: IRAK4 degrader in Ph2 for AD + hidradenitis suppurativa", "Sanofi $1.45B option deal \u2014 largest degrader partnership", "STAT6 degrader (KT-621): undruggable target, IL-4/IL-13" ], "fontSize": 1000, "_maxChars": 320, "_maxLines": 5, "_overflow": false, "_charCount": 235, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 6, "header": "Degrader Pipeline Value Est. ($B rNPV)", "content": { "type": "chart", "series": [ { "data": [ 1.2, 0.8, 0.7, 0.4, 0.9 ], "name": "rNPV ($B)" } ], "barColor": "#4472C4", "gridLeft": 110, "chartType": "bar", "categories": [ "KT-474 (AD)", "KT-474 (HS)", "KT-621", "KT-413", "Platform" ], "gridBottom": 60, "horizontal": true, "valueSuffix": "B", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Degrader Field Competitive Landscape", "content": { "data": { "rows": [ [ "Arvinas", "ARV-110", "AR (PROTAC)", "Phase 3" ], [ "Kymera", "KT-474", "IRAK4", "Phase 2" ], [ "C3 Bio", "CFT8634", "BRD9 glue", "Phase 1" ], [ "Nurix", "NX-5948", "BTK deg.", "Phase 1" ], [ "BMS", "CC-92480", "IKZF glue", "Phase 2" ] ], "headers": [ "Company", "Lead", "Target", "Stage" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 3 ], "rowHeight": 0.16, "_cellMaxChars": [ 22, 15, 15, 15 ], "_headersMaxChars": [ 44, 30, 30, 30 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Investment Thesis & Key Metrics", "content": { "type": "statGrid", "items": [ { "label": "rNPV (base)", "value": "$4.0B", "sublabel": "12% cost of capital" }, { "label": "Mkt cap discount", "value": "60%", "sublabel": "vs. rNPV; undervalued" }, { "label": "M&A fit", "value": "AbbVie/BMS", "sublabel": "Immunology/oncology gap" }, { "label": "Key catalyst", "value": "H1 2026", "sublabel": "KT-474 Ph2 AD readout" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Sanofi deal = external validation done", "KT-474 AD readout = binary re-rating", "STAT6 is a \\$2B+ undruggable unlock", "Trading at deep discount to rNPV" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 141, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Kymera Therapeutics: Targeted Degraders", "footer": "Source: Kymera Therapeutics SEC filings, ClinicalTrials.gov, Evaluate Pharma. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 39, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 0, 1, 0, 0 ], "name": "_offset", "color": "transparent" }, { "data": [ 3, 3, 3, 0, 0 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 3, 0, 0, 0, 0 ], "name": "Phase 2/3", "color": "#5A8CD4" }, { "data": [ 0, 2, 3, 3, 4 ], "name": "Phase 1", "color": "#A9D18E" }, { "data": [ 0, 0, 0, 0, 2 ], "name": "Preclinical", "color": "#D9D9D9" } ], "stacked": true, "gridLeft": 150, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "KT-474 (IRAK4 deg., AD/HS)", "KT-413 (IRAK4 DLBCL)", "KT-621 (STAT6 deg.)", "KT-253 (MDM2 deg.)", "Undisclosed (AR-v7)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "KT-474", "Ph2 AD EASI score", "H1 2026", "V.High" ], [ "KT-474", "Ph2 HS IGA data", "H2 2025", "High" ], [ "KT-621", "Ph1 safety data", "H2 2025", "Medium" ], [ "KT-413", "Ph1 NHL ORR", "H1 2026", "Medium" ], [ "KT-253", "Ph1 dose escalation", "H1 2026", "Low" ] ], "headers": [ "Program", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "E3 Ligase Landscape (Platform Depth)", "content": { "data": { "rows": [ [ "CRBN", "KT-253", "BMS/J&J/Arvinas", "Yes" ], [ "DCAF16", "KT-474", "Nurix, C3", "Yes" ], [ "VHL", "Undiscl.", "Arvinas", "Yes" ], [ "MDM2", "KT-253", "Ascentage", "Partial" ], [ "RNF4", "Preclin.", "None", "No" ] ], "headers": [ "Ligase", "Kymera assets", "Competitors", "Drugged?" ], "fontSize": 900, "colWidths": [ 3, 3, 4, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 15, 15, 22, 15 ], "_headersMaxChars": [ 30, 30, 44, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Kymera Therapeutics: Pipeline Timeline", "footer": "Source: Kymera Therapeutics SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 3, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$0.9B", "sublabel": "NASDAQ: CMPS" }, { "label": "Cash", "value": "$210M", "sublabel": "~2 yr runway" }, { "label": "Lead program", "value": "Ph2b/3", "sublabel": "COMP360 TRD" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why COMPASS Is the Bellwether CNS Startup", "content": { "type": "bulletList", "items": [ "First synthetic psilocybin in Phase 2b/3 for TRD globally", "Ph2b: 29% remission at 25mg vs 7.6% placebo (p<0.001)", "Strong IP portfolio with therapeutic use patents", "FDA breakthrough for anorexia; expanding to PTSD" ], "fontSize": 1000, "_maxChars": 320, "_maxLines": 5, "_overflow": false, "_charCount": 206, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 6, "header": "TRD Market Size & Addressable Patients", "content": { "type": "chart", "series": [ { "data": [ 5, 8, 1, 21 ], "name": "Addressable Patients (M)" } ], "barColor": "#4472C4", "gridLeft": 120, "chartType": "bar", "categories": [ "TRD (US)", "PTSD (US)", "Anorexia (US)", "Addiction (US)" ], "gridBottom": 60, "horizontal": true, "valueSuffix": "M", "showBarValues": true, "valueDecimals": 1 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Psychedelic / Novel CNS Landscape", "content": { "data": { "rows": [ [ "COMPASS", "COMP360", "Psilocybin TRD", "Ph 2b/3" ], [ "Atai Life", "PCN-101", "R-ketamine", "Phase 2" ], [ "Lykos Tx", "MDMA-AT", "PTSD", "NDA filed" ], [ "Perception", "PCN-101", "5-HT2A", "Phase 2" ], [ "Small Ph.", "SPL026", "DMT", "Phase 2" ] ], "headers": [ "Company", "Asset", "Target", "Stage" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 3 ], "rowHeight": 0.16, "_cellMaxChars": [ 22, 15, 15, 15 ], "_headersMaxChars": [ 44, 30, 30, 30 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Investment Thesis & Key Metrics", "content": { "type": "statGrid", "items": [ { "label": "rNPV (base)", "value": "$1.4B", "sublabel": "TRD alone, 15% CoC" }, { "label": "Upside case", "value": "$3.5B+", "sublabel": "PTSD + anorexia label" }, { "label": "M&A fit", "value": "JNJ / AbbVie", "sublabel": "Neuroscience rebuild" }, { "label": "Key risk", "value": "FDA pathway", "sublabel": "Novel regulatory hurdle" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "Ph2b data is unusually clean signal", "Anorexia BT designation = optionality", "JNJ neuroscience rebuild = strategic fit", "Cash runway is the primary risk now" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 147, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "COMPASS Pathways: Psychedelic Medicine", "footer": "Source: COMPASS Pathways SEC filings, ClinicalTrials.gov, Evaluate Pharma. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 38, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 1, 2, 0, 0 ], "name": "_offset", "color": "transparent" }, { "data": [ 3, 0, 0, 0, 0 ], "name": "Phase 2/3", "color": "#5A8CD4" }, { "data": [ 3, 0, 0, 0, 3 ], "name": "Phase 3", "color": "#7030A0" }, { "data": [ 2, 0, 0, 0, 0 ], "name": "NDA/Filing", "color": "#ED7D31" }, { "data": [ 0, 4, 4, 0, 3 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 0, 0, 0, 2, 0 ], "name": "Preclinical", "color": "#D9D9D9" }, { "data": [ 0, 0, 0, 3, 0 ], "name": "Phase 1", "color": "#A9D18E" } ], "stacked": true, "gridLeft": 150, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "COMP360 (psilocybin TRD)", "COMP360 (PTSD)", "COMP360 (anorexia)", "COMP054 (next-gen analog)", "Digital therapy companion" ], "gridBottom": 60, "horizontal": true, "showBarValues": false }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "COMP360 TRD", "Ph2b/3 primary EP", "H2 2025", "V.High" ], [ "COMP360 TRD", "NDA submission", "H1 2028", "High" ], [ "COMP360 PTSD", "Ph2 ORR data", "H1 2026", "High" ], [ "COMP360 AN", "Ph2 enroll complete", "H2 2026", "Medium" ], [ "COMP054", "Ph1 first-in-human", "H1 2027", "Medium" ] ], "headers": [ "Program", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Regulatory & Reimbursement Challenges", "content": { "data": { "rows": [ [ "FDA REMS", "Expected", "High", "Spravato model" ], [ "DEA scheduling", "Schedule I", "Medium", "NDA triggers" ], [ "Payer coverage", "Uncertain", "Medium", "Value-based Rx" ], [ "IP durability", "Strong", "High", "Polymorph + use" ], [ "Clinic infra", "Scaling", "Medium", "COMPASS network" ] ], "headers": [ "Issue", "Status", "Probability", "Mitigation" ], "fontSize": 900, "colWidths": [ 4, 3, 2, 4 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 15, 9, 22 ], "_headersMaxChars": [ 44, 30, 18, 44 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "COMPASS Pathways: Pipeline Timeline", "footer": "Source: COMPASS Pathways SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 35, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 3, "children": [ { "span": 6, "header": "Company Snapshot", "content": { "type": "statGrid", "items": [ { "label": "Market Cap", "value": "~$2.1B", "sublabel": "NASDAQ: RXRX" }, { "label": "Cash", "value": "$560M", "sublabel": "~2.5 yr runway" }, { "label": "Nvidia stake", "value": "$50M", "sublabel": "Strategic investor" } ] }, "_headerMaxChars": 44 }, { "span": 6, "header": "Why Recursion Is the AI Biotech Benchmark", "content": { "type": "bulletList", "items": [ "OS maps 50B+ cell images; largest phenomics dataset in pharma", "Roche/Genentech paid $150M upfront for AI model access (2023)", "Acquired Exscientia (2024): combines generative + phenomics AI", "REC-994 & REC-2282 in human trials = AI pipeline is real, not hype" ], "fontSize": 1000, "_maxChars": 320, "_maxLines": 5, "_overflow": false, "_charCount": 250, "_lineCount": 5, "lineSpacing": 0.9, "_charsPerLine": 64, "_maxCharsPerItem": 64 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 6, "children": [ { "span": 6, "header": "AI Drug Discovery Cost Advantage", "content": { "type": "chart", "series": [ { "data": [ 60, 36, 18 ], "name": "Avg. time to IND (months)" } ], "barColor": "#4472C4", "gridLeft": 120, "chartType": "bar", "categories": [ "Trad. discovery", "AI-assisted", "Recursion OS" ], "gridBottom": 60, "horizontal": true, "showBarValues": true, "valueDecimals": 0 }, "_headerMaxChars": 44 }, { "span": 6, "header": "AI Pharma Competitive Landscape", "content": { "data": { "rows": [ [ "Recursion", "Phenomics", "Roche/Nvda", "Phase 2" ], [ "Exscientia", "Gen. design", "Sanofi", "Acquired" ], [ "Insilico", "Gen. design", "Pfizer", "Phase 2" ], [ "Isomorphic", "AlphaFold3", "Lilly/AZ", "Discovery" ], [ "BioNTech", "mRNA + AI", "In-house", "Phase 2" ] ], "headers": [ "Company", "AI Method", "Partner", "Stage" ], "fontSize": 900, "colWidths": [ 4, 4, 3, 3 ], "rowHeight": 0.16, "_cellMaxChars": [ 20, 20, 14, 14 ], "_headersMaxChars": [ 40, 40, 28, 28 ] }, "type": "table", "_maxRows": 12, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" }, { "span": 3, "children": [ { "span": 8, "header": "Investment Thesis & Key Metrics", "content": { "type": "statGrid", "items": [ { "label": "OS data moat", "value": "50B+ images", "sublabel": "10x nearest competitor" }, { "label": "Revenue model", "value": "Dual", "sublabel": "Pipeline + AI licensing" }, { "label": "M&A fit", "value": "Roche / AZ", "sublabel": "AI platform acqui-hire" }, { "label": "Key catalyst", "value": "2025\u201326", "sublabel": "REC-994 Ph2 readout" } ] }, "_headerMaxChars": 59 }, { "span": 4, "header": "Our View", "content": { "type": "bulletList", "items": [ "AI hype real; pipeline must deliver", "Exscientia merger = stronger gen. AI", "Roche deal = strategic upside option", "REC-994 is the make-or-break proof pt" ], "fontSize": 1000, "_maxChars": 200, "_maxLines": 5, "_overflow": false, "_charCount": 144, "_lineCount": 4, "lineSpacing": 0.9, "_charsPerLine": 40, "_maxCharsPerItem": 40 }, "_headerMaxChars": 28 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Recursion Pharma: AI-Native Drug Co.", "footer": "Source: Recursion Pharmaceuticals SEC filings, ClinicalTrials.gov, PitchBook. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 36, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "children": [ { "span": 8, "header": "Development Timeline (Gantt \u2014 H1\u2019s from H1 2025)", "content": { "type": "chart", "series": [ { "data": [ 0, 0, 1, 0, 1 ], "name": "_offset", "color": "transparent" }, { "data": [ 3, 3, 3, 0, 0 ], "name": "Phase 2", "color": "#4472C4" }, { "data": [ 4, 0, 0, 0, 0 ], "name": "Phase 3", "color": "#7030A0" }, { "data": [ 0, 3, 0, 0, 0 ], "name": "Phase 2/3", "color": "#5A8CD4" }, { "data": [ 0, 0, 3, 0, 0 ], "name": "Phase 1/2", "color": "#A9D18E" }, { "data": [ 0, 0, 0, 2, 2 ], "name": "Preclinical", "color": "#D9D9D9" }, { "data": [ 0, 0, 0, 3, 3 ], "name": "Phase 1", "color": "#A9D18E" } ], "stacked": true, "gridLeft": 150, "xAxisMax": 8, "xAxisMin": 0, "chartType": "bar", "categories": [ "REC-994 (CCM, cerebral)", "REC-2282 (NF2 schwannoma)", "REC-3599 (TBCK-encepha.)", "REC-4539 (AI-gen., onco.)", "REC-1245 (AI-gen., immuno)" ], "gridBottom": 60, "horizontal": true, "showBarValues": false }, "_headerMaxChars": 92 }, { "span": 4, "children": [ { "span": 6, "header": "Key Catalysts", "content": { "data": { "rows": [ [ "REC-994", "Ph2 CCM primary EP", "H2 2025", "V.High" ], [ "REC-2282", "Ph2 NF2 ORR", "H1 2026", "High" ], [ "REC-3599", "Ph1/2 first-in-human", "H1 2026", "Medium" ], [ "REC-4539", "IND filing (AI-gen.)", "H2 2025", "Medium" ], [ "OS v3.0", "Model release + deals", "H1 2026", "High" ] ], "headers": [ "Program", "Catalyst", "When", "Impact" ], "fontSize": 900, "colWidths": [ 4, 4, 2, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 22, 9, 15 ], "_headersMaxChars": [ 44, 44, 18, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 }, { "span": 6, "header": "Recursion OS Platform Metrics", "content": { "data": { "rows": [ [ "Cell images", "50B+", "~1B", "50x data" ], [ "Time to IND", "18 mo", "60 mo", "3.3x faster" ], [ "Hit rate", "~22%", "~5%", "4x higher" ], [ "Cost / cmpd", "$500", "$5,000", "10x cheaper" ], [ "Active programs", "50+", "N/A", "Breadth" ] ], "headers": [ "Metric", "Recursion", "Industry avg.", "Edge" ], "fontSize": 900, "colWidths": [ 4, 3, 3, 3 ], "rowHeight": 0.17, "_cellMaxChars": [ 22, 15, 15, 15 ], "_headersMaxChars": [ 44, 30, 30, 30 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 44 } ], "direction": "row" } ], "direction": "col" }, "type": "grid", "title": "Recursion Pharma: Pipeline Timeline", "footer": "Source: Recursion Pharmaceuticals SEC filings, ClinicalTrials.gov. Timelines are estimates. Jan 2026.", "sectionLabel": "THEMES BEYOND GLP-1", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 35, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "body": { "gap": 0, "children": [ { "span": 8, "padding": 0.5, "children": [ { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "10.", "type": "text", "color": "#405363", "anchor": "b", "fontSize": 6400, "_maxChars": 26, "_maxLines": 2, "_overflow": false, "_charCount": 3, "_lineCount": 1, "_charsPerLine": 13 } }, { "span": 6, "content": { "bold": true, "font": "Garamond", "text": "INVESTMENT IMPLICATIONS", "type": "text", "color": "#012179", "anchor": "t", "fontSize": 2000, "_maxChars": 344, "_maxLines": 8, "_overflow": false, "_charCount": 23, "_lineCount": 1, "_charsPerLine": 43 } } ], "direction": "col" }, { "span": 4, "content": { "url": "https://r2.bankops.ai/generated/1772024946596-414192eaa27c.png", "type": "image", "prompt": "professional subtle luxury molecule pattern with color #012179", "source": "ai" }, "background": "#4472C4" } ], "direction": "row" }, "type": "grid" }, { "body": { "children": [ { "span": 7, "children": [ { "span": 6, "header": "Framework for Evaluating Biotech Opportunities", "content": { "data": { "rows": [ [ "Platform vs. Asset", "Modular, reusable platform", "One drug, one indication" ], [ "Acquirer Logic", "Fits 2+ Big Pharma buyers", "Only one plausible acquirer" ], [ "Mechanism Validation", "Phase 2 human PoC in hand", "Preclinical only, animals" ], [ "China Angle", "Western rights to derisked asset", "No China competition" ], [ "Capital Efficiency", "Lean burn, 18+ month runway", "High burn, no near-term data" ] ], "headers": [ "Dimension", "Strong Signal", "Weak Signal" ], "fontSize": 900, "colWidths": [ 3, 5, 4 ], "rowHeight": 0.26, "_cellMaxChars": [ 20, 36, 28 ], "_headersMaxChars": [ 40, 72, 56 ] }, "type": "table", "_maxRows": 7, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 52 }, { "span": 6, "header": "Sector Allocation View: 2026", "content": { "type": "chart", "series": [ { "data": [ 8, 9, 8, 7, 7, 8, 6 ], "name": "Relative Conviction (1\u201310)" } ], "barColor": "#4472C4", "gridLeft": 140, "chartType": "bar", "categories": [ "Metabolic/Obesity", "Oncology Platforms", "Radiopharmaceuticals", "CNS/Neuropsychiatry", "Rare Disease", "Protein Degraders", "Gene Editing" ], "gridBottom": 20, "horizontal": true, "showBarValues": true }, "_headerMaxChars": 52 } ], "direction": "col" }, { "span": 5, "children": [ { "span": 6, "header": "The Five Contrarian Calls", "content": { "type": "bulletList", "items": [ "Allogeneic CAR-T will work: Precision BioSciences, Allogene \u2014 give it 18 months", "China out-licensing is biggest alpha Western IB firms underserve today", "ADC manufacturing: Lonza, Samsung Biologics are infrastructure plays", "Radiopharm Ac-225 supply will be biotech's semiconductor shortage" ], "fontSize": 1000, "_maxChars": 676, "_maxLines": 13, "_overflow": false, "_charCount": 282, "_lineCount": 8, "lineSpacing": 0.9, "_charsPerLine": 52, "_maxCharsPerItem": 156 }, "_headerMaxChars": 36 }, { "span": 6, "header": "Near-Term Catalysts to Watch", "content": { "data": { "rows": [ [ "CagriSema Ph3 data", "Q2 2026", "GLP-1 combo thesis" ], [ "Lilly oral GLP-1", "H1 2026", "Oral form. race" ], [ "BMS mol. glue PDUFA", "Mid 2026", "Degrader signal" ], [ "Ivonescimab NSCLC", "H2 2026", "China ADC signal" ], [ "FDA leadership set", "Q1\u2013Q2 2026", "Approval pace" ] ], "headers": [ "Catalyst", "Timeline", "Impact" ], "fontSize": 900, "colWidths": [ 5, 3, 4 ], "rowHeight": 0.32, "_cellMaxChars": [ 25, 13, 19 ], "_headersMaxChars": [ 50, 26, 38 ] }, "type": "table", "_maxRows": 6, "_overflow": false, "_rowCount": 5 }, "_headerMaxChars": 36 } ], "direction": "col" } ], "direction": "row" }, "type": "grid", "title": "Investment Implications & Key Takeaways", "footer": "Source: Investment Banking MD analysis; Evaluate Pharma; FactSet | This presentation represents a point-in-view, not investment advice", "sectionLabel": "INVESTMENT IMPLICATIONS", "_titleMaxChars": 41, "_titleMaxLines": 1, "_titleOverflow": false, "_footerMaxChars": 184, "_titleCharCount": 39, "_titleLineCount": 1, "_titleCharsPerLine": 41, "_sectionLabelMaxChars": 122 }, { "type": "grid", "title": "", "body": { "direction": "row", "children": [ { "span": 1 }, { "span": 7, "direction": "col", "children": [ { "content": { "type": "text", "text": "The Barbell Is a Feature, Not a Bug", "fontSize": 2400, "anchor": "b", "bold": true } }, { "content": { "type": "text", "text": "The volatility of the past three years has stress-tested biotech to reveal what truly matters: platform breadth, mechanism validation, and acquirer fit. The companies that emerge from this barbell moment with genuine platform technology and de-risked science will be the defining deals of 2026\u20132028.\n\nThe greatest risk in biotech is not science failure \u2014 it is strategic irrelevance.", "fontSize": 1200 } } ] }, { "span": 4 } ] } } ], "slideSize": { "width": 13.333, "height": 7.5 } }